Amicus Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Amicus Therapeutics Inc together

Penke I guess you are interested in Amicus Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amicus Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Amicus Therapeutics Inc

I send you an email if I find something interesting about Amicus Therapeutics Inc.

Quick analysis of Amicus Therapeutics Inc (30 sec.)

What can you expect buying and holding a share of Amicus Therapeutics Inc? (30 sec.)

How much money do you get?

$0.01

When do you have the money?

1 year

How often do you get paid?

10.0%

What is your share worth?

Current worth

$0.54

Expected worth in 1 year

$0.67

How sure are you?

42.5%

+ What do you gain per year?

Total Gains per Share

$0.14

Return On Investment

1.3%

For what price can you sell your share?

Current Price per Share

$10.82

Expected price per share

$8.9375 - $11.97

How sure are you?

50%

1. Valuation of Amicus Therapeutics Inc (5 min.)

Live pricePrice per Share (EOD)

$10.82

Book Value per Share

$0.54

Intrinsic Value Per Share

$-4.12 - $5.58

Total Value Per Share

$-3.57 - $6.13

My calculation of the intrinsic value of Amicus Therapeutics Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.15) 3Y: ($-0.13) TTM: ($-0.06)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($0.01) TTM: ($0.07)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.58	$-0.36	$-0.60 - $-0.27
2	$-1.11	$-0.48	$-0.58 - $-0.04
3	$-1.61	$-0.37	$-0.57 - $0.20
4	$-2.06	$-0.06	$-0.56 - $0.44
5	$-2.48	$0.45	$-0.54 - $0.68
6	$-2.86	$1.15	$-0.53 - $0.91
7	$-3.22	$2.02	$-0.52 - $1.15
8	$-3.54	$3.06	$-0.50 - $1.39
9	$-3.84	$4.25	$-0.49 - $1.63
10	$-4.12	$5.58	$-0.48 - $1.86

2. Growth of Amicus Therapeutics Inc (5 min.)

Is Amicus Therapeutics Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$160.1m	$166.9m	-$40m	-31.5%

How much money is Amicus Therapeutics Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$37.8m	-$59.1m	$21.2m	56.1%
Net Profit Margin	-39.3%	-72.4%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Amicus Therapeutics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#287 / 1011

Most Revenue
#97 / 1011

Most Profit
#848 / 1011

Most Efficient
#522 / 1011

What can you expect buying and holding a share of Amicus Therapeutics Inc? (5 min.)

Welcome investor! Amicus Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Amicus Therapeutics Inc.

What can you expect buying and holding a share of Amicus Therapeutics Inc?

First you should know what it really means to hold a share of Amicus Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Amicus Therapeutics Inc is $10.82. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Amicus Therapeutics Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amicus Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.54. Based on the TTM, the Book Value Change Per Share is $0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Amicus Therapeutics Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.11	-1.1%	-0.13	-1.2%	-0.20	-1.9%	-0.22	-2.0%	-0.20	-1.8%
Usd Book Value Change Per Share	0.09	0.8%	0.03	0.3%	-0.16	-1.4%	-0.03	-0.3%	0.01	0.1%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.01	0.1%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.09	0.8%	0.03	0.3%	-0.15	-1.4%	-0.03	-0.3%	0.01	0.1%
Usd Price Per Share	14.19	-	12.50	-	10.72	-	11.94	-	10.81	-
Price to Earnings Ratio	-30.96	-	-27.39	-	-15.07	-	-16.25	-	-16.69	-
Price-to-Total Gains Ratio	154.63	-	127.18	-	-155.18	-	-38.74	-	10.48	-
Price to Book Ratio	26.17	-	29.59	-	20.65	-	16.29	-	14.85	-
Price-to-Total Gains Ratio	154.63	-	127.18	-	-155.18	-	-38.74	-	10.48	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	10.82
Number of shares	92

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.03	-0.03
Usd Total Gains Per Share	0.03	-0.03
Gains per Quarter (92 shares)	3.17	-2.61
Gains per Year (92 shares)	12.67	-10.43

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	1	12	3	1	-11	-20
2	2	23	16	2	-23	-30
3	3	35	29	3	-34	-40
4	4	46	42	4	-46	-50
5	6	58	55	5	-57	-60
6	7	69	68	6	-68	-70
7	8	81	81	7	-80	-80
8	9	93	94	8	-91	-90
9	10	104	107	9	-102	-100
10	11	116	120	10	-114	-110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	4.0	0.0	0.0%	0.0	12.0	0.0	0.0%	0.0	20.0	0.0	0.0%	0.0	40.0	0.0	0.0%	1.0	69.0	1.0	1.4%
Book Value Change Per Share	3.0	1.0	0.0	75.0%	4.0	8.0	0.0	33.3%	6.0	14.0	0.0	30.0%	17.0	23.0	0.0	42.5%	25.0	46.0	0.0	35.2%
Dividend per Share	2.0	0.0	2.0	50.0%	4.0	0.0	8.0	33.3%	4.0	0.0	16.0	20.0%	4.0	0.0	36.0	10.0%	4.0	0.0	67.0	5.6%
Total Gains per Share	3.0	1.0	0.0	75.0%	4.0	8.0	0.0	33.3%	6.0	14.0	0.0	30.0%	17.0	23.0	0.0	42.5%	25.0	46.0	0.0	35.2%

Fundamentals of Amicus Therapeutics Inc

About Amicus Therapeutics Inc

https://amicusrx.com
Biotechnology
517
47 Hulfish Street, Princeton, NJ, United States, 08542
Google Maps Bing Maps

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 08:06:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Amicus Therapeutics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Amicus Therapeutics Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
A Net Profit Margin of -29.4% means that $-0.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amicus Therapeutics Inc:

The MRQ is -29.4%. The company is making a huge loss. -2
The TTM is -39.3%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-29.4%	TTM	-39.3%	+9.9%
TTM	-39.3%	YOY	-72.4%	+33.0%
TTM	-39.3%	5Y	-101.9%	+62.5%
5Y	-101.9%	10Y	-552.1%	+450.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-29.4%	-200.1%	+170.7%
TTM	-39.3%	-216.8%	+177.5%
YOY	-72.4%	-288.3%	+215.9%
5Y	-101.9%	-449.1%	+347.2%
10Y	-552.1%	-605.5%	+53.4%

Measures how much net profit Amicus Therapeutics Inc earns for each $1 of revenue.

Revenue is the amount of profit Amicus Therapeutics Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Amicus Therapeutics Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Amicus Therapeutics Inc makes more profit. This shows the investor how efficiently Amicus Therapeutics Inc is operating in general and compared to other companies in the same industry. Amicus Therapeutics Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Amicus Therapeutics Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Amicus Therapeutics Inc is -0.29. This means that Amicus Therapeutics Inc earned $-0.29 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Amicus Therapeutics Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Amicus Therapeutics Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Amicus Therapeutics Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Amicus Therapeutics Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Amicus Therapeutics Inc = -33,843
Total revenue MRQ Amicus Therapeutics Inc = 115,082
$-33,843 / $115,082 = -0.29 or -29.4%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Amicus Therapeutics Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
-4.4% Return on Assets means that Amicus Therapeutics Inc generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amicus Therapeutics Inc:

The MRQ is -4.4%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -5.2%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-4.4%	TTM	-5.2%	+0.8%
TTM	-5.2%	YOY	-7.5%	+2.4%
TTM	-5.2%	5Y	-7.9%	+2.7%
5Y	-7.9%	10Y	-8.4%	+0.6%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-4.4%	-13.3%	+8.9%
TTM	-5.2%	-12.8%	+7.6%
YOY	-7.5%	-11.7%	+4.2%
5Y	-7.9%	-13.9%	+6.0%
10Y	-8.4%	-15.7%	+7.3%

Shows how efficient Amicus Therapeutics Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Amicus Therapeutics Inc is using its resources to generate profit. If the return on assets (-4.4%) from Amicus Therapeutics Inc are higher than the Biotechnology mean (-13.3%) that means Amicus Therapeutics Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Amicus Therapeutics Inc is -4.4%. This means the company generated $-0.04 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Amicus Therapeutics Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Amicus Therapeutics Inc = -33,843
Total assets MRQ (balance sheet) from Amicus Therapeutics Inc = 777,880
-33,843 / 777,880 = -0.04 or -4.4%

ROA is an important ratio as it will tell you how effectively Amicus Therapeutics Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Amicus Therapeutics Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
-21.1% Return on Equity means Amicus Therapeutics Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amicus Therapeutics Inc:

The MRQ is -21.1%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -31.9%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-21.1%	TTM	-31.9%	+10.8%
TTM	-31.9%	YOY	-35.5%	+3.6%
TTM	-31.9%	5Y	-25.6%	-6.3%
5Y	-25.6%	10Y	-23.5%	-2.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-21.1%	-16.9%	-4.2%
TTM	-31.9%	-16.1%	-15.8%
YOY	-35.5%	-15.1%	-20.4%
5Y	-25.6%	-19.3%	-6.3%
10Y	-23.5%	-20.2%	-3.3%

Shows how efficient Amicus Therapeutics Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Amicus Therapeutics Inc is -21.1%. This means Amicus Therapeutics Inc generated $-0.21 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if Amicus Therapeutics Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Amicus Therapeutics Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Amicus Therapeutics Inc = -33,843
Shareholders equity (balance sheet) MRQ Amicus Therapeutics Inc = 160,174
-33,843 / 160,174 = -0.21 or -21.1%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Amicus Therapeutics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Amicus Therapeutics Inc is operating .

Measures how much profit Amicus Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
An Operating Margin of -3.2% means the company generated $-0.03 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amicus Therapeutics Inc:

The MRQ is -3.2%. The company is operating very inefficient. -2
The TTM is -26.3%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-3.2%	TTM	-26.3%	+23.0%
TTM	-26.3%	YOY	-62.7%	+36.4%
TTM	-26.3%	5Y	-88.8%	+62.5%
5Y	-88.8%	10Y	-511.6%	+422.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-3.2%	-296.2%	+293.0%
TTM	-26.3%	-232.5%	+206.2%
YOY	-62.7%	-298.2%	+235.5%
5Y	-88.8%	-492.1%	+403.3%
10Y	-511.6%	-632.4%	+120.8%

Measures how efficient Amicus Therapeutics Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Amicus Therapeutics Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Amicus Therapeutics Inc is -3.2%. This means that Amicus Therapeutics Inc earned $-0.03 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Amicus Therapeutics Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Amicus Therapeutics Inc = -3,692
Total revenue MRQ Amicus Therapeutics Inc = 115,082
$-3,692 / $115,082 = -0.03 or -3.2%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Amicus Therapeutics Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 1.03 means that the operating costs are $1.03 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amicus Therapeutics Inc:

The MRQ is 1.032. The company is inefficient in keeping operating costs low. -1
The TTM is 1.193. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.032	TTM	1.193	-0.161
TTM	1.193	YOY	1.627	-0.434
TTM	1.193	5Y	1.825	-0.632
5Y	1.825	10Y	6.721	-4.896

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.032	3.231	-2.199
TTM	1.193	3.310	-2.117
YOY	1.627	3.890	-2.263
5Y	1.825	5.739	-3.914
10Y	6.721	7.876	-1.155

Measures how efficient Amicus Therapeutics Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Amicus Therapeutics Inc is 103.2%. This means that Amicus Therapeutics Inc earned $1.03 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Amicus Therapeutics Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(13,506 +105,268) \ 115,082 = 1.03

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Amicus Therapeutics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Amicus Therapeutics Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 2.88 means the company has $2.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amicus Therapeutics Inc:

The MRQ is 2.881. The company is able to pay all its short-term debts. +1
The TTM is 2.805. The company is able to pay all its short-term debts. +1

Trends

Current period		Compared to		+/-
MRQ	2.881	TTM	2.805	+0.075
TTM	2.805	YOY	3.214	-0.409
TTM	2.805	5Y	4.262	-1.456
5Y	4.262	10Y	5.279	-1.018

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.881	3.890	-1.009
TTM	2.805	4.173	-1.368
YOY	3.214	5.344	-2.130
5Y	4.262	6.126	-1.864
10Y	5.279	6.448	-1.169

Measures if Amicus Therapeutics Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Amicus Therapeutics Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Amicus Therapeutics Inc is 2.88. This means Amicus Therapeutics Inc has $2.88 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Amicus Therapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
483,061 \ 167,689) = 2.88

The current ratio measures if Amicus Therapeutics Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Amicus Therapeutics Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Amicus Therapeutics Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Amicus Therapeutics Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Amicus Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
A Quick Ratio of 2.46 means the company can pay off $2.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amicus Therapeutics Inc:

The MRQ is 2.463. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 2.563. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	2.463	TTM	2.563	-0.100
TTM	2.563	YOY	3.776	-1.213
TTM	2.563	5Y	5.687	-3.124
5Y	5.687	10Y	7.984	-2.297

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.463	3.514	-1.051
TTM	2.563	3.998	-1.435
YOY	3.776	5.380	-1.604
5Y	5.687	6.105	-0.418
10Y	7.984	6.404	+1.580

Measures if Amicus Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Amicus Therapeutics Inc can pay off its short term debts. This shows if Amicus Therapeutics Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Amicus Therapeutics Inc is 2.46. This means that Amicus Therapeutics Inc can pay off $2.46 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Amicus Therapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Amicus Therapeutics Inc: (286,200 + 39,206 +87,632) / 167,689 = 2.46

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Amicus Therapeutics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Amicus Therapeutics Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Amicus Therapeutics Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.79 means that Amicus Therapeutics Inc assets are financed with 79.4% credit (debt) and the remaining percentage (100% - 79.4%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Amicus Therapeutics Inc:

The MRQ is 0.794. The company is just able to pay all its debts by selling its assets.
The TTM is 0.830. The company is just able to pay all its debts by selling its assets.

Trends

Current period		Compared to		+/-
MRQ	0.794	TTM	0.830	-0.036
TTM	0.830	YOY	0.788	+0.043
TTM	0.830	5Y	0.650	+0.181
5Y	0.650	10Y	0.599	+0.051

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.794	0.339	+0.455
TTM	0.830	0.336	+0.494
YOY	0.788	0.271	+0.517
5Y	0.650	0.366	+0.284
10Y	0.599	0.389	+0.210

Measures how much % of Amicus Therapeutics Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Amicus Therapeutics Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Amicus Therapeutics Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Amicus Therapeutics Inc is 0.79. This means means that Amicus Therapeutics Inc is financed with 79.4% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Amicus Therapeutics Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Amicus Therapeutics Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
617,706 \ 777,880 = 79.4% or 0.79.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Amicus Therapeutics Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 385.6% means that company has $3.86 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amicus Therapeutics Inc:

The MRQ is 3.856. The company is unable to pay all its debts with equity. -1
The TTM is 4.991. The company is unable to pay all its debts with equity. -1

Trends

Current period		Compared to		+/-
MRQ	3.856	TTM	4.991	-1.135
TTM	4.991	YOY	3.924	+1.067
TTM	4.991	5Y	2.618	+2.373
5Y	2.618	10Y	2.022	+0.596

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.856	0.388	+3.468
TTM	4.991	0.402	+4.589
YOY	3.924	0.335	+3.589
5Y	2.618	0.426	+2.192
10Y	2.022	0.461	+1.561

Measures if Amicus Therapeutics Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Amicus Therapeutics Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Amicus Therapeutics Inc is 3.86. This means that Amicus Therapeutics Inc can pay off $3.86 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Amicus Therapeutics Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
617,706 \ 160,174 = 3.86 or 385.6%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Amicus Therapeutics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amicus Therapeutics Inc generates.

Above 15 is considered overpriced but always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
A PE ratio of -30.96 means the investor is paying $-30.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amicus Therapeutics Inc:

The EOD is -23.609. Based on the earnings, the company is expensive. -2
The MRQ is -30.963. Based on the earnings, the company is expensive. -2
The TTM is -27.390. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-23.609	MRQ	-30.963	+7.353
MRQ	-30.963	TTM	-27.390	-3.573
TTM	-27.390	YOY	-15.066	-12.324
TTM	-27.390	5Y	-16.250	-11.140
5Y	-16.250	10Y	-16.693	+0.443

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-23.609	-2.264	-21.345
MRQ	-30.963	-2.629	-28.334
TTM	-27.390	-2.680	-24.710
YOY	-15.066	-4.145	-10.921
5Y	-16.250	-6.257	-9.993
10Y	-16.693	-6.254	-10.439

Measures how much money you pay for each share for every $1 in earnings Amicus Therapeutics Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Amicus Therapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Amicus Therapeutics Inc is -30.96. This means the investor is paying $-30.96 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how Amicus Therapeutics Inc is performing over time. The most recent quarter might be important if Amicus Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Amicus Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Amicus Therapeutics Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 293,594 = EPS
PE ratio MRQ = -30.96

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amicus Therapeutics Inc:

The EOD is 462.658. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is 606.758. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is 123.180. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	462.658	MRQ	606.758	-144.100
MRQ	606.758	TTM	123.180	+483.578
TTM	123.180	YOY	-34.657	+157.837
TTM	123.180	5Y	6.973	+116.206
5Y	6.973	10Y	-7.193	+14.167

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	462.658	-2.973	+465.631
MRQ	606.758	-3.333	+610.091
TTM	123.180	-3.553	+126.733
YOY	-34.657	-5.605	-29.052
5Y	6.973	-8.376	+15.349
10Y	-7.193	-8.865	+1.672

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Amicus Therapeutics Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 26.17 means the investor is paying $26.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amicus Therapeutics Inc:

The EOD is 19.954. Based on the equity, the company is expensive. -2
The MRQ is 26.168. Based on the equity, the company is expensive. -2
The TTM is 29.587. Based on the equity, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	19.954	MRQ	26.168	-6.215
MRQ	26.168	TTM	29.587	-3.418
TTM	29.587	YOY	20.647	+8.939
TTM	29.587	5Y	16.291	+13.295
5Y	16.291	10Y	14.852	+1.440

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	19.954	1.896	+18.058
MRQ	26.168	2.115	+24.053
TTM	29.587	2.093	+27.494
YOY	20.647	2.884	+17.763
5Y	16.291	3.542	+12.749
10Y	14.852	3.916	+10.936

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amicus Therapeutics Inc.

3.1. Institutions holding Amicus Therapeutics Inc

Institutions are holding 109.578% of the shares of Amicus Therapeutics Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Vanguard Group Inc	9.646	0.0088	28492486	1360613	5.0148
2023-12-31	Perceptive Advisors LLC	9.4987	8.887	28057456	364539	1.3164
2023-12-31	venBio Select Advisor LLC	9.2761	5.3704	27400000	0	0
2023-12-31	BlackRock Inc	7.7825	0.0083	22988139	2046362	9.7717
2023-12-31	JPMorgan Chase & Co	6.0425	0.0243	17848531	4839102	37.1969
2023-09-30	Redmile Group, LLC	5.7365	9.8035	16944621	-2622340	-13.4019
2023-12-31	Wellington Management Company LLP	5.1425	0.0402	15190024	7666335	101.896
2023-12-31	Morgan Stanley - Brokerage Accounts	4.5121	0.0167	13327897	2579205	23.9955
2023-12-31	State Street Corporation	4.4563	0.0091	13163085	1790649	15.7455
2023-12-31	William Blair Investment Management, LLC	3.943	0.481	11647026	1270263	12.2414
2023-12-31	HHG PLC	3.8957	0.0974	11507129	-3426892	-22.9469
2023-12-31	Palo Alto Investors, LLC	3.512	13.2626	10373715	-150307	-1.4282
2023-12-31	Macquarie Group Ltd	2.4426	0.1183	7215010	2358	0.0327
2023-12-31	Pictet Asset Manangement SA	2.368	0.1095	6994597	-1402914	-16.7063
2023-12-31	Geode Capital Management, LLC	2.0148	0.0088	5951295	345129	6.1562
2023-12-31	Deutsche Bank AG	1.9564	0.0418	5778744	5632116	3841.0917
2023-12-31	Fiera Capital Corporation	1.7136	0.2205	5061644	-24227	-0.4764
2023-12-31	American Century Companies Inc	1.5512	0.0447	4582067	238197	5.4835
2023-12-31	Goldman Sachs Group Inc	1.4373	0.0054	4245490	1727406	68.6
2023-12-31	Northern Trust Corp	0.9631	0.0073	2844751	12821	0.4527
Total		87.8909	38.5656	259613707	+22248415	+8.6%

3.2. Funds holding Amicus Therapeutics Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Vanguard Health Care Inv	3.4379	0.3105	10154896	6087245	149.6501
2024-02-29	Vanguard Total Stock Mkt Idx Inv	3.212	0.0079	9487817	-32785	-0.3444
2024-02-29	Vanguard Small Cap Index	2.5591	0.069	7559261	70856	0.9462
2024-03-28	iShares Russell 2000 ETF	2.4002	0.1275	7089836	3420	0.0483
2024-03-28	SPDR® S&P Biotech ETF	2.1029	0.9691	6211659	78360	1.2776
2023-12-31	Macquarie US Small Cap Core Equity	1.8154	1.018	5362316	0	0
2024-02-29	Delaware Small Cap Core I	1.7944	0.9231	5300283	1486	0.028
2023-12-31	Janus Henderson Contrarian D	1.7417	1.601	5144567	-2100811	-28.9952
2023-12-31	Janus Henderson US Opportunistic Alpha	1.7417	1.5899	5144567	-2100811	-28.9952
2024-02-29	Vanguard Small Cap Growth Index Inv	1.4359	0.1558	4241522	60388	1.4443
2023-12-31	American Century US Opport. Mid Cap Gr	1.385	1.0588	4090973	220431	5.6951
2023-12-31	American Century Heritage Inv	1.385	1.0595	4090973	220431	5.6951
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.3263	0.0492	3917619	-20959	-0.5321
2024-02-29	JPMorgan Small Cap Growth A	1.2328	1.153	3641619	-3321	-0.0911
2024-02-29	JPM Global Healthcare C (acc) USD	1.086	0.8729	3207765	-57466	-1.7599
2024-02-29	JPMorgan Mid Cap Growth I	1.024	0.3468	3024712	0	0
2024-01-31	Fidelity Small Cap Index	0.9719	0.1439	2870739	45846	1.6229
2024-03-28	iShares Russell 2000 Growth ETF	0.8517	0.2543	2515757	-2925	-0.1161
2024-01-31	Fiera SMID Growth	0.8185	1.8895	2417611	41445	1.7442
2024-02-29	Fidelity Select Biotechnology	0.8013	0.6172	2366934	143200	6.4396
Total		33.1237	14.2169	97841426	+2654030	+2.7%

3.3. Insider Transactions

Insiders are holding 0.754% of the shares of Amicus Therapeutics Inc.

Date	Owner	Type	Amount	Price
2024-03-05	Margaret G Mcglynn	SELL	7500	13.4
2024-02-15	John F Crowley	SELL	31614	13.81
2024-02-15	David Michael Clark	SELL	4427	14
2024-02-15	Bradley L Campbell	SELL	4167	14
2024-02-06	Ellen Rosenberg	SELL	400	13
2024-01-22	John F Crowley	SELL	55327	12.36
2024-01-16	John F Crowley	SELL	31614	12.78
2024-01-10	John F Crowley	SELL	31614	13.65
2024-01-09	David Michael Clark	SELL	1384	14
2024-01-08	Samantha Prout	SELL	30767	14
2024-01-02	Bradley L Campbell	SELL	15833	14.23
2024-01-02	Ellen Rosenberg	SELL	30000	14.21
2023-12-27	Ellen Rosenberg	SELL	5000	14.07
2023-12-26	Samantha Prout	SELL	7659	14
2023-12-19	Jeff Castelli	SELL	17500	13.25
2023-12-15	John F Crowley	SELL	6043	12.66
2023-12-01	John F Crowley	SELL	6043	11.08
2023-12-01	Bradley L Campbell	SELL	11702	11.08
2023-11-15	John F Crowley	SELL	6043	10.84
2023-11-01	Bradley L Campbell	SELL	11700	10.97

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Amicus Therapeutics Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.092	0.031	+192%	-0.156	+270%	-0.031	+134%	0.010	+848%
Book Value Per Share	-	-	0.542	0.429	+26%	0.565	-4%	0.977	-44%	0.989	-45%
Current Ratio	-	-	2.881	2.805	+3%	3.214	-10%	4.262	-32%	5.279	-45%
Debt To Asset Ratio	-	-	0.794	0.830	-4%	0.788	+1%	0.650	+22%	0.599	+33%
Debt To Equity Ratio	-	-	3.856	4.991	-23%	3.924	-2%	2.618	+47%	2.022	+91%
Dividend Per Share	-	-	-	0.003	-100%	0.010	-100%	0.003	-100%	0.001	-100%
Eps	-	-	-0.115	-0.128	+12%	-0.200	+75%	-0.215	+88%	-0.195	+70%
Free Cash Flow Per Share	-	-	0.006	-0.065	+1207%	-0.144	+2566%	-0.163	+2880%	-0.152	+2705%
Free Cash Flow To Equity Per Share	-	-	0.034	-0.013	+137%	-0.150	+547%	-0.036	+207%	0.029	+14%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	5.584	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-4.116	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.357	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.580	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-0.374	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.607	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	0.451	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-2.479	-	-	-	-	-	-	-	-
Market Cap	3196044146.560	-31%	4191484883.520	3693431938.080	+13%	3165028930.720	+32%	3527840440.656	+19%	3194164745.064	+31%
Net Profit Margin	-	-	-0.294	-0.393	+34%	-0.724	+146%	-1.019	+246%	-5.521	+1777%
Operating Margin	-	-	-0.032	-0.263	+718%	-0.627	+1854%	-0.888	+2668%	-5.116	+15846%
Operating Ratio	-	-	1.032	1.193	-14%	1.627	-37%	1.825	-43%	6.721	-85%
Pb Ratio	19.954	-31%	26.168	29.587	-12%	20.647	+27%	16.291	+61%	14.852	+76%
Pe Ratio	-23.609	+24%	-30.963	-27.390	-12%	-15.066	-51%	-16.250	-48%	-16.693	-46%
Price Per Share	10.820	-31%	14.190	12.500	+14%	10.715	+32%	11.943	+19%	10.813	+31%
Price To Free Cash Flow Ratio	462.658	-31%	606.758	123.180	+393%	-34.657	+106%	6.973	+8601%	-7.193	+101%
Price To Total Gains Ratio	117.907	-31%	154.630	127.182	+22%	-155.177	+200%	-38.743	+125%	10.480	+1375%
Quick Ratio	-	-	2.463	2.563	-4%	3.776	-35%	5.687	-57%	7.984	-69%
Return On Assets	-	-	-0.044	-0.052	+19%	-0.075	+73%	-0.079	+81%	-0.084	+94%
Return On Equity	-	-	-0.211	-0.319	+51%	-0.355	+68%	-0.256	+21%	-0.235	+11%
Total Gains Per Share	-	-	0.092	0.034	+167%	-0.146	+259%	-0.028	+131%	0.011	+736%
Usd Book Value	-	-	160174000.000	126891250.000	+26%	166913500.000	-4%	288531850.000	-44%	292078525.000	-45%
Usd Book Value Change Per Share	-	-	0.092	0.031	+192%	-0.156	+270%	-0.031	+134%	0.010	+848%
Usd Book Value Per Share	-	-	0.542	0.429	+26%	0.565	-4%	0.977	-44%	0.989	-45%
Usd Dividend Per Share	-	-	-	0.003	-100%	0.010	-100%	0.003	-100%	0.001	-100%
Usd Eps	-	-	-0.115	-0.128	+12%	-0.200	+75%	-0.215	+88%	-0.195	+70%
Usd Free Cash Flow	-	-	1727000.000	-19132750.000	+1208%	-42585250.000	+2566%	-48009600.000	+2880%	-44995350.000	+2705%
Usd Free Cash Flow Per Share	-	-	0.006	-0.065	+1207%	-0.144	+2566%	-0.163	+2880%	-0.152	+2705%
Usd Free Cash Flow To Equity Per Share	-	-	0.034	-0.013	+137%	-0.150	+547%	-0.036	+207%	0.029	+14%
Usd Market Cap	3196044146.560	-31%	4191484883.520	3693431938.080	+13%	3165028930.720	+32%	3527840440.656	+19%	3194164745.064	+31%
Usd Price Per Share	10.820	-31%	14.190	12.500	+14%	10.715	+32%	11.943	+19%	10.813	+31%
Usd Profit	-	-	-33843000.000	-37896000.000	+12%	-59142000.000	+75%	-63592600.000	+88%	-57648275.000	+70%
Usd Revenue	-	-	115082000.000	99839000.000	+15%	82308250.000	+40%	73861300.000	+56%	40258975.000	+186%
Usd Total Gains Per Share	-	-	0.092	0.034	+167%	-0.146	+259%	-0.028	+131%	0.011	+736%
	EOD	+3 -5	MRQ	TTM	+30 -5	YOY	+24 -11	5Y	+23 -12	10Y	+23 -12

4.2. Fundamental Score

Let's check the fundamental score of Amicus Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-23.609
Price to Book Ratio (EOD)	Between	0-1	19.954
Net Profit Margin (MRQ)	Greater than	0	-0.294
Operating Margin (MRQ)	Greater than	0	-0.032
Quick Ratio (MRQ)	Greater than	1	2.463
Current Ratio (MRQ)	Greater than	1	2.881
Debt to Asset Ratio (MRQ)	Less than	1	0.794
Debt to Equity Ratio (MRQ)	Less than	1	3.856
Return on Equity (MRQ)	Greater than	0.15	-0.211
Return on Assets (MRQ)	Greater than	0.05	-0.044
Total			3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Amicus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	39.815
Ma 20	Greater than	Ma 50	11.217
Ma 50	Greater than	Ma 100	12.153
Ma 100	Greater than	Ma 200	12.408
Open	Greater than	Close	10.700
Total			1/5 (20.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	777,880
Total Liabilities	617,706
Total Stockholder Equity	160,174

	As reported
Total Liabilities	617,706
Total Stockholder Equity	+ 160,174
Total Assets	= 777,880

Assets

Total Assets	777,880
Total Current Assets	483,061
Long-term Assets	294,819

Total Current Assets

Total Current Assets (as reported)	483,061
Cash And Cash Equivalents	246,994
Short-term Investments	39,206
Net Receivables	87,632
Inventory	59,696
Other Current Assets	49,533
Total Current Assets (calculated)	483,061
+/-	0

Long-term Assets

Long-term Assets (as reported)	294,819
Property Plant Equipment	57,979
Goodwill	197,797
Intangible Assets	20,490
Long-term Assets Other	15,470
Long-term Assets (calculated)	291,736
+/-	3,083

Liabilities & Shareholders' Equity

Total Current Liabilities	167,689
Long-term Liabilities	450,017
Total Stockholder Equity	160,174

Total Current Liabilities

Total Current Liabilities (as reported)	167,689
Short-term Debt	8,324
Accounts payable	15,120
Other Current Liabilities	131,811
Total Current Liabilities (calculated)	155,255
+/-	12,434

Long-term Liabilities

Long-term Liabilities (as reported)	450,017
Long term Debt	387,858
Capital Lease Obligations Min Short Term Debt	48,877
Long-term Liabilities Other	13,282
Long-term Liabilities (calculated)	450,017
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	160,174
Common Stock	2,918
Retained Earnings	-2,684,074
Accumulated Other Comprehensive Income	5,312
Other Stockholders Equity	2,836,018
Total Stockholder Equity (calculated)	160,174
+/-	0

Other

Capital Stock	2,918
Cash and Short Term Investments	286,200
Common Stock Shares Outstanding	293,594
Current Deferred Revenue	12,434
Liabilities and Stockholders Equity	777,880
Net Debt	198,065
Net Invested Capital	548,032
Net Working Capital	315,372
Property Plant and Equipment Gross	83,408
Short Long Term Debt Total	445,059

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

> Total Assets

5,073
0
0
0
28,670
0
0
0
59,646
73,048
131,583
124,833
167,097
159,532
151,083
143,165
128,773
116,375
108,676
98,892
85,370
88,137
74,886
63,762
112,552
102,551
90,288
78,867
69,795
120,801
111,598
118,211
110,088
93,216
82,335
69,106
127,563
112,357
117,994
125,487
209,967
192,616
403,913
986,692
908,384
862,907
914,006
918,180
1,036,845
993,381
938,966
680,779
627,024
870,005
825,889
838,589
789,951
764,702
918,033
882,292
850,207
738,349
701,451
900,542
886,520
810,034
786,892
956,675
905,140
826,938
800,589
759,528
724,167
700,519
730,093
764,084
777,880

777,880

764,084

730,093

700,519

724,167

759,528

800,589

826,938

905,140

956,675

786,892

810,034

886,520

900,542

701,451

738,349

850,207

882,292

918,033

764,702

789,951

838,589

825,889

870,005

627,024

680,779

938,966

993,381

1,036,845

918,180

914,006

862,907

908,384

986,692

403,913

192,616

209,967

125,487

117,994

112,357

127,563

69,106

82,335

93,216

110,088

118,211

111,598

120,801

69,795

78,867

90,288

102,551

112,552

63,762

74,886

88,137

85,370

98,892

108,676

116,375

128,773

143,165

151,083

159,532

167,097

124,833

131,583

73,048

59,646

28,670

5,073

> Total Current Assets

0
0
0
0
24,859
0
0
0
55,020
68,093
127,155
120,653
163,040
155,634
146,621
138,245
123,587
111,032
103,083
93,576
80,486
83,936
71,147
60,478
109,681
100,047
88,099
76,394
66,648
115,286
105,667
112,476
104,617
87,812
77,178
64,308
88,278
73,450
79,422
87,237
154,577
151,251
364,997
240,053
216,601
168,513
217,674
221,712
340,064
296,207
240,989
431,013
391,965
592,033
576,230
601,034
551,096
483,046
634,876
576,657
520,073
407,949
383,884
585,277
579,469
502,891
480,502
650,540
596,834
518,900
497,643
458,539
423,816
399,697
432,822
463,256
483,061

483,061

463,256

432,822

399,697

423,816

458,539

497,643

518,900

596,834

650,540

480,502

502,891

579,469

585,277

383,884

407,949

520,073

576,657

634,876

483,046

551,096

601,034

576,230

592,033

391,965

431,013

240,989

296,207

340,064

221,712

217,674

168,513

216,601

240,053

364,997

151,251

154,577

87,237

79,422

73,450

88,278

64,308

77,178

87,812

104,617

112,476

105,667

115,286

66,648

76,394

88,099

100,047

109,681

60,478

71,147

83,936

80,486

93,576

103,083

111,032

123,587

138,245

146,621

155,634

163,040

120,653

127,155

68,093

55,020

24,859

Cash And Cash Equivalents

257
0
0
0
6,449
0
0
0
12,127
19,853
26,494
19,933
44,188
18,203
12,315
19,855
28,073
23,242
15,760
20,487
19,339
33,562
24,622
22,097
29,572
27,662
25,789
22,810
25,668
24,523
28,858
24,273
33,971
26,736
23,476
30,047
43,640
27,533
41,904
19,671
24,074
28,827
249,023
19,439
69,485
23,510
63,656
33,115
187,026
44,755
37,394
64,133
49,060
114,322
73,311
201,827
79,749
96,349
220,578
166,319
142,837
123,231
164,573
210,631
163,240
184,833
176,538
385,903
245,197
233,317
235,639
277,592
148,813
160,602
211,307
263,320
246,994

246,994

263,320

211,307

160,602

148,813

277,592

235,639

233,317

245,197

385,903

176,538

184,833

163,240

210,631

164,573

123,231

142,837

166,319

220,578

96,349

79,749

201,827

73,311

114,322

49,060

64,133

37,394

44,755

187,026

33,115

63,656

23,510

69,485

19,439

249,023

28,827

24,074

19,671

41,904

27,533

43,640

30,047

23,476

26,736

33,971

24,273

28,858

24,523

25,668

22,810

25,789

27,662

29,572

22,097

24,622

33,562

19,339

20,487

15,760

23,242

28,073

19,855

12,315

18,203

44,188

19,933

26,494

19,853

12,127

6,449

257

Short-term Investments

4,079
0
0
0
17,969
0
0
0
42,572
47,853
99,229
99,475
117,339
136,355
132,635
116,400
93,051
85,806
84,670
68,784
58,885
47,870
44,444
35,484
77,873
66,112
57,257
46,718
30,034
83,673
66,914
81,942
65,151
58,015
50,700
30,448
38,360
44,121
36,092
65,511
127,601
119,940
112,396
217,070
144,548
142,341
150,494
179,284
143,325
235,087
189,838
347,388
309,502
448,198
465,641
362,556
424,403
341,978
355,078
347,875
309,903
215,642
145,017
298,451
320,029
232,596
206,530
171,057
237,299
177,878
151,202
77,108
144,782
106,507
54,319
16,980
39,206

39,206

16,980

54,319

106,507

144,782

77,108

151,202

177,878

237,299

171,057

206,530

232,596

320,029

298,451

145,017

215,642

309,903

347,875

355,078

341,978

424,403

362,556

465,641

448,198

309,502

347,388

189,838

235,087

143,325

179,284

150,494

142,341

144,548

217,070

112,396

119,940

127,601

65,511

36,092

44,121

38,360

30,448

50,700

58,015

65,151

81,942

66,914

83,673

30,034

46,718

57,257

66,112

77,873

35,484

44,444

47,870

58,885

68,784

84,670

85,806

93,051

116,400

132,635

136,355

117,339

99,475

99,229

47,853

42,572

17,969

4,079

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,969
1,977
3,828
5,043
4,301
7,237
3,184
3,225
1,308
1,024
2,121
759
38
475
293
1,304
0
0
0
1,304
0
864
864
1,304
1,875
3,786
5,974
9,464
10,836
15,077
14,189
21,962
22,960
28,709
33,731
33,284
40,555
43,040
44,828
46,923
44,931
49,172
51,427
52,672
52,421
52,556
52,303
66,196
68,178
63,716
73,331
87,632

87,632

73,331

63,716

68,178

66,196

52,303

52,556

52,421

52,672

51,427

49,172

44,931

46,923

44,828

43,040

40,555

33,284

33,731

28,709

22,960

21,962

14,189

15,077

10,836

9,464

5,974

3,786

1,875

1,304

864

1,304

293

475

759

2,121

1,024

1,308

3,225

3,184

7,237

4,301

5,043

3,828

1,977

3,969

Inventory

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
194
3,251
3,416
3,698
3,948
7,272
4,623
8,070
7,769
6,311
8,390
8,167
10,395
9,154
14,041
12,831
12,979
15,767
19,556
18,801
24,086
22,072
26,818
24,324
20,879
13,272
23,816
27,004
51,381
56,936
59,696

59,696

56,936

51,381

27,004

23,816

13,272

20,879

24,324

26,818

22,072

24,086

18,801

19,556

15,767

12,979

12,831

14,041

9,154

10,395

8,167

8,390

6,311

7,769

8,070

4,623

7,272

3,948

3,698

3,416

3,251

194

> Long-term Assets

0
0
0
0
3,811
0
0
0
4,625
4,955
4,428
4,180
4,057
3,898
4,462
4,920
5,186
5,343
5,593
5,316
4,884
4,201
3,739
3,284
2,871
2,504
2,189
2,473
3,147
5,515
5,931
5,735
5,471
5,404
5,157
4,798
39,285
38,907
38,572
38,250
55,390
41,365
38,916
746,639
691,783
694,394
696,332
696,468
696,781
697,174
697,977
249,766
235,059
277,972
249,659
237,555
238,855
281,656
283,157
305,635
330,134
330,400
317,567
315,265
307,051
307,143
306,390
306,135
308,306
308,038
302,946
300,989
300,351
300,822
297,271
300,828
294,819

294,819

300,828

297,271

300,822

300,351

300,989

302,946

308,038

308,306

306,135

306,390

307,143

307,051

315,265

317,567

330,400

330,134

305,635

283,157

281,656

238,855

237,555

249,659

277,972

235,059

249,766

697,977

697,174

696,781

696,468

696,332

694,394

691,783

746,639

38,916

41,365

55,390

38,250

38,572

38,907

39,285

4,798

5,157

5,404

5,471

5,735

5,931

5,515

3,147

2,473

2,189

2,504

2,871

3,284

3,739

4,201

4,884

5,316

5,593

5,343

5,186

4,920

4,462

3,898

4,057

4,180

4,428

4,955

4,625

3,811

Property Plant Equipment

541
0
0
0
3,279
0
0
0
4,358
4,265
4,161
3,913
3,790
3,631
4,195
4,416
4,919
5,076
5,326
5,049
4,399
3,934
3,472
3,017
2,604
2,237
1,922
1,759
2,438
5,073
5,489
5,293
5,029
4,962
4,715
4,356
4,120
3,748
3,444
3,129
2,811
3,056
3,379
3,855
6,178
8,413
10,178
10,183
9,816
9,745
10,471
9,641
9,062
8,910
9,111
10,659
11,375
49,594
50,325
70,487
81,020
80,189
70,894
68,015
67,159
65,808
64,393
63,261
63,082
62,053
64,104
62,320
60,312
59,889
58,280
60,583
57,979

57,979

60,583

58,280

59,889

60,312

62,320

64,104

62,053

63,082

63,261

64,393

65,808

67,159

68,015

70,894

80,189

81,020

70,487

50,325

49,594

11,375

10,659

9,111

8,910

9,062

9,641

10,471

9,745

9,816

10,183

10,178

8,413

6,178

3,855

3,379

3,056

2,811

3,129

3,444

3,748

4,120

4,356

4,715

4,962

5,029

5,293

5,489

5,073

2,438

1,759

1,922

2,237

2,604

3,017

3,472

3,934

4,399

5,049

5,326

5,076

4,919

4,416

4,195

3,631

3,790

3,913

4,161

4,265

4,358

3,279

541

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,613
11,613
11,613
11,613
11,613
11,613
11,613
207,564
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797
197,797

197,797

207,564

11,613

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,464
2,804
0
15,428
0
0
0
0
0
0
0
15,109
0
42,673
13,836
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

13,836

42,673

15,109

15,428

2,804

17,464

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,000
23,000
23,000
23,000
23,000
23,000
23,000
518,810
486,700
486,700
486,700
486,700
486,700
486,700
486,700
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
23,000
22,964
22,145
21,318
20,490

20,490

21,318

22,145

22,964

23,000

486,700

518,810

23,000

Long-term Assets Other

0
0
0
0
532
0
0
0
267
690
267
267
267
267
267
504
267
267
267
267
485
267
267
267
267
267
267
714
709
442
442
442
442
442
442
442
552
546
515
508
502
892
924
982
1,108
1,484
1,657
1,788
2,468
2,932
3,009
-4,967
5,200
-873
-550
6,099
6,683
11,265
12,035
14,351
28,317
29,414
25,876
-277,049
19,095
20,538
21,200
22,077
24,427
25,188
8,893
9,001
19,242
20,172
19,049
21,130
15,470

15,470

21,130

19,049

20,172

19,242

9,001

8,893

25,188

24,427

22,077

21,200

20,538

19,095

-277,049

25,876

29,414

28,317

14,351

12,035

11,265

6,683

6,099

-550

-873

5,200

-4,967

3,009

2,932

2,468

1,788

1,657

1,484

1,108

982

924

892

502

508

515

546

552

442

709

714

267

485

267

504

267

690

267

532

> Total Liabilities

922
0
0
0
64,500
0
0
0
137,161
159,330
8,918
11,144
63,800
61,847
61,417
60,150
57,730
56,118
60,035
61,730
13,537
13,943
10,524
13,271
47,618
49,490
45,681
42,078
40,203
40,025
38,431
41,452
40,868
39,879
42,776
42,617
81,812
81,273
81,686
82,210
87,789
88,606
75,011
607,937
560,550
551,275
579,763
581,625
676,694
682,603
672,074
271,099
274,174
348,388
263,994
427,638
447,039
313,034
317,975
334,025
373,782
335,755
340,498
580,273
600,140
559,138
572,982
580,046
597,771
588,321
627,164
626,963
601,120
597,946
618,512
630,847
617,706

617,706

630,847

618,512

597,946

601,120

626,963

627,164

588,321

597,771

580,046

572,982

559,138

600,140

580,273

340,498

335,755

373,782

334,025

317,975

313,034

447,039

427,638

263,994

348,388

274,174

271,099

672,074

682,603

676,694

581,625

579,763

551,275

560,550

607,937

75,011

88,606

87,789

82,210

81,686

81,273

81,812

42,617

42,776

39,879

40,868

41,452

38,431

40,025

40,203

42,078

45,681

49,490

47,618

13,271

10,524

13,943

13,537

61,730

60,035

56,118

57,730

60,150

61,417

61,847

63,800

11,144

8,918

159,330

137,161

64,500

922

> Total Current Liabilities

922
0
0
0
2,593
0
0
0
10,207
8,567
6,965
9,571
15,793
14,810
15,298
14,937
13,378
12,554
15,237
17,082
11,193
8,838
7,147
8,148
16,223
16,636
16,878
18,625
19,256
17,765
17,812
9,930
9,243
7,995
9,967
8,598
10,461
9,366
11,171
13,824
20,185
21,022
16,901
35,865
73,616
64,427
80,459
85,612
110,959
109,596
100,683
68,159
70,040
140,705
52,963
65,880
86,125
65,869
89,547
93,081
128,812
91,714
108,300
111,727
129,676
99,652
111,993
121,102
145,975
129,699
164,625
164,650
139,018
138,385
159,235
169,454
167,689

167,689

169,454

159,235

138,385

139,018

164,650

164,625

129,699

145,975

121,102

111,993

99,652

129,676

111,727

108,300

91,714

128,812

93,081

89,547

65,869

86,125

65,880

52,963

140,705

70,040

68,159

100,683

109,596

110,959

85,612

80,459

64,427

73,616

35,865

16,901

21,022

20,185

13,824

11,171

9,366

10,461

8,598

9,967

7,995

9,243

9,930

17,812

17,765

19,256

18,625

16,878

16,636

16,223

8,148

7,147

8,838

11,193

17,082

15,237

12,554

13,378

14,937

15,298

14,810

15,793

9,571

6,965

8,567

10,207

2,593

922

Short-term Debt

0
0
0
0
279
0
0
0
1,307
1,342
1,504
1,521
1,527
1,420
1,258
1,090
877
695
603
1,545
1,558
1,480
1,395
1,339
1,293
1,253
1,253
1,253
1,044
1,129
816
502
398
398
398
398
299
199
1,253
2,493
3,840
5,189
0
0
41,601
0
56,000
55,992
283
56,101
159,171
161,635
307
80,577
169,440
0
0
2,523
2,678
6,356
7,189
7,503
8,516
7,368
6,872
6,764
7,106
7,175
7,409
7,255
7,543
7,536
8,552
8,005
7,840
7,765
8,324

8,324

7,765

7,840

8,005

8,552

7,536

7,543

7,255

7,409

7,175

7,106

6,764

6,872

7,368

8,516

7,503

7,189

6,356

2,678

2,523

169,440

80,577

307

161,635

159,171

56,101

283

55,992

56,000

41,601

5,189

3,840

2,493

1,253

199

299

398

502

816

1,129

1,044

1,253

1,293

1,339

1,395

1,480

1,558

1,545

603

695

877

1,090

1,258

1,420

1,527

1,521

1,504

1,342

1,307

279

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,840
0
0
0
41,601
0
56,000
55,992
154,747
56,101
159,171
161,635
164,474
166,768
169,440
0
0
2,421
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2,421

169,440

166,768

164,474

161,635

159,171

56,101

154,747

55,992

56,000

41,601

3,840

Accounts payable

590
0
0
0
906
0
0
0
1,195
1,738
338
535
530
1,050
10,745
9,804
8,796
8,683
10,988
12,759
3,837
7,358
5,752
6,809
1,971
7,418
7,019
8,098
2,576
8,449
9,067
9,428
8,845
6,427
9,018
8,166
2,146
9,167
9,918
11,331
16,345
15,833
16,901
30,565
16,477
22,501
23,828
29,013
12,905
39,645
35,645
53,709
7,867
43,678
41,613
54,330
6,606
60,596
84,119
81,475
120,373
16,239
14,306
14,764
17,063
16,110
13,762
24,474
21,513
22,914
23,113
12,046
15,413
24,965
13,522
23,154
15,120

15,120

23,154

13,522

24,965

15,413

12,046

23,113

22,914

21,513

24,474

13,762

16,110

17,063

14,764

14,306

16,239

120,373

81,475

84,119

60,596

6,606

54,330

41,613

43,678

7,867

53,709

35,645

39,645

12,905

29,013

23,828

22,501

16,477

30,565

16,901

15,833

16,345

11,331

9,918

9,167

2,146

8,166

9,018

6,427

8,845

9,428

9,067

8,449

2,576

8,098

7,019

7,418

1,971

6,809

5,752

7,358

3,837

12,759

10,988

8,683

8,796

9,804

10,745

1,050

530

535

338

1,738

1,195

906

590

Other Current Liabilities

158
0
0
0
1,407
0
0
0
7,704
5,487
5,123
7,515
9,935
7,728
3,295
4,043
10,514
8,683
868
12,759
9,635
7,358
5,752
6,809
8,290
7,418
7,019
8,098
7,132
8,449
9,067
9,428
6,730
1,170
551
34
8,016
9,366
11,171
13,824
10,471
21,022
0
5,300
57,139
41,926
56,631
56,599
265
69,951
65,038
14,450
61,866
97,027
11,350
11,550
79,519
2,750
2,750
5,250
-3,801
67,972
85,478
84,544
100,845
76,778
91,125
89,453
112,123
99,530
129,039
140,138
110,114
105,415
137,873
138,535
131,811

131,811

138,535

137,873

105,415

110,114

140,138

129,039

99,530

112,123

89,453

91,125

76,778

100,845

84,544

85,478

67,972

-3,801

5,250

2,750

79,519

11,550

11,350

97,027

61,866

14,450

65,038

69,951

265

56,599

56,631

41,926

57,139

5,300

21,022

10,471

13,824

11,171

9,366

8,016

551

1,170

6,730

9,428

9,067

8,449

7,132

8,098

7,019

7,418

8,290

6,809

5,752

7,358

9,635

12,759

868

8,683

10,514

4,043

3,295

7,728

9,935

7,515

5,123

5,487

7,704

1,407

158

> Long-term Liabilities

0
0
0
0
61,907
0
0
0
126,954
150,763
1,953
1,573
48,007
47,037
46,119
45,213
44,352
43,564
44,798
44,648
2,344
5,105
3,377
5,123
31,395
32,854
28,803
23,453
20,947
22,260
20,619
31,522
31,625
31,884
32,809
34,019
71,351
71,907
70,515
68,386
67,604
67,584
58,110
572,072
486,934
486,848
499,304
496,013
565,735
573,007
571,391
202,940
204,134
207,683
211,031
361,758
360,914
247,165
228,428
240,944
244,970
244,041
232,198
468,546
470,464
459,486
460,989
458,944
451,796
458,622
462,539
462,313
462,102
459,561
459,277
461,393
450,017

450,017

461,393

459,277

459,561

462,102

462,313

462,539

458,622

451,796

458,944

460,989

459,486

470,464

468,546

232,198

244,041

244,970

240,944

228,428

247,165

360,914

361,758

211,031

207,683

204,134

202,940

571,391

573,007

565,735

496,013

499,304

486,848

486,934

572,072

58,110

67,584

67,604

68,386

70,515

71,907

71,351

34,019

32,809

31,884

31,625

31,522

20,619

22,260

20,947

23,453

28,803

32,854

31,395

5,123

3,377

5,105

2,344

44,648

44,798

43,564

44,352

45,213

46,119

47,037

48,007

1,573

1,953

150,763

126,954

61,907

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
418
104
0
597
498
398
299
199
100
0
14,174
14,216
13,104
11,809
10,510
9,208
0
0
41,601
38,509
21,851
21,977
154,464
156,859
159,171
161,635
164,167
166,768
169,440
318,808
321,740
168,818
149,064
149,260
149,505
149,736
150,037
388,584
389,254
389,789
390,434
388,719
389,357
0
0
391,319
391,990
392,658
393,350
0
0

393,350

392,658

391,990

391,319

389,357

388,719

390,434

389,789

389,254

388,584

150,037

149,736

149,505

149,260

149,064

168,818

321,740

318,808

169,440

166,768

164,167

161,635

159,171

156,859

154,464

21,977

21,851

38,509

41,601

9,208

10,510

11,809

13,104

14,216

14,174

100

199

299

398

498

597

104

418

Warrants

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,442
3,889
908
0
0
0
0
0
0
0
0
0
0
0
8,755
12,298
16,076
16,076
16,076
16,076
16,076
16,076
16,076
16,076
13,063
13,063
13,063
12,387
12,387
12,387
12,387
12,387
12,387
12,387
12,387
0
0
83
83
83
83
83
83
83
71
0
0

12,387

13,063

16,076

12,298

8,755

908

3,889

4,442

Other Liabilities

0
0
0
0
704
0
0
0
609
672
0
0
46,813
46,119
45,424
44,730
44,035
43,341
42,647
41,952
0
3,098
1,707
3,766
30,351
32,123
28,385
23,349
20,947
21,663
20,121
31,124
31,326
31,685
32,709
34,019
47,991
48,505
48,225
47,391
47,908
49,190
48,924
314,859
269,114
272,120
257,791
253,770
237,500
242,328
238,351
32,119
33,502
40,915
41,591
42,950
39,037
42,247
43,105
41,998
41,934
41,783
38,495
35,335
35,606
25,266
26,354
26,730
19,076
18,171
19,043
18,982
18,534
0
14,951
14,868
0

14,868

14,951

18,534

18,982

19,043

18,171

19,076

26,730

26,354

25,266

35,606

35,335

38,495

41,783

41,934

41,998

43,105

42,247

39,037

42,950

41,591

40,915

33,502

32,119

238,351

242,328

237,500

253,770

257,791

272,120

269,114

314,859

48,924

49,190

47,908

47,391

48,225

48,505

47,991

34,019

32,709

31,685

31,326

31,124

20,121

21,663

20,947

23,349

28,385

32,123

30,351

3,766

1,707

3,098

41,952

42,647

43,341

44,035

44,730

45,424

46,119

46,813

672

609

704

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,319
20,659
18,999
17,339
15,679
27,235
30,418
31,685
32,709
34,019
45,863
45,863
45,863
45,863
45,806
45,806
45,806
243,833
211,975
211,975
211,975
211,975
195,677
195,726
190,775
26,092
20,621
20,621
20,621
20,621
16,621
17,871
17,871
15,371
13,957
13,957
13,957
13,957
12,302
12,302
23,000
12,302
10,836
5,906
23,000
10,836
9,595
5,906
5,906
0
0

5,906

9,595

10,836

23,000

5,906

10,836

12,302

23,000

12,302

13,957

15,371

17,871

16,621

20,621

26,092

190,775

195,726

195,677

211,975

243,833

45,806

45,863

34,019

32,709

31,685

30,418

27,235

15,679

17,339

18,999

20,659

22,319

> Total Stockholder Equity

4,151
0
0
0
-35,830
0
0
0
-77,515
-86,282
122,665
113,689
103,297
97,685
89,666
83,015
71,043
60,257
48,641
37,162
71,833
74,194
64,362
50,491
64,934
53,061
44,607
36,789
29,592
80,776
73,167
76,759
69,220
53,337
39,559
26,489
45,751
31,084
36,308
43,277
122,178
104,010
328,902
378,755
347,834
311,632
334,243
336,555
360,151
310,778
266,892
409,680
352,850
521,617
561,895
410,951
342,912
451,668
600,058
548,267
476,425
402,594
360,953
320,269
286,380
250,896
213,910
376,629
307,369
238,617
173,425
132,565
123,047
102,573
111,581
133,237
160,174

160,174

133,237

111,581

102,573

123,047

132,565

173,425

238,617

307,369

376,629

213,910

250,896

286,380

320,269

360,953

402,594

476,425

548,267

600,058

451,668

342,912

410,951

561,895

521,617

352,850

409,680

266,892

310,778

360,151

336,555

334,243

311,632

347,834

378,755

328,902

104,010

122,178

43,277

36,308

31,084

45,751

26,489

39,559

53,337

69,220

76,759

73,167

80,776

29,592

36,789

44,607

53,061

64,934

50,491

64,362

74,194

71,833

37,162

48,641

60,257

71,043

83,015

89,666

97,685

103,297

113,689

122,665

-86,282

-77,515

-35,830

4,151

Common Stock

23
0
0
0
40
0
0
0
70
82
283
284
285
285
285
285
287
287
287
287
287
337
337
337
406
406
406
407
407
524
524
554
556
556
556
556
679
703
789
853
1,015
1,024
1,241
1,304
1,306
1,308
1,399
1,478
1,480
1,482
1,485
1,707
1,721
1,929
1,939
1,941
1,942
2,347
2,589
2,591
2,598
2,607
2,614
2,626
2,650
2,680
2,685
2,805
2,808
2,809
2,811
2,813
2,815
2,820
2,856
2,890
2,918

2,918

2,890

2,856

2,820

2,815

2,813

2,811

2,809

2,808

2,805

2,685

2,680

2,650

2,626

2,614

2,607

2,598

2,591

2,589

2,347

1,942

1,941

1,939

1,929

1,721

1,707

1,485

1,482

1,480

1,478

1,399

1,308

1,306

1,304

1,241

1,024

1,015

853

789

703

679

556

554

524

407

406

337

287

285

284

283

Retained Earnings Total Equity

-2,628,654

-2,585,422

-2,532,490

-2,476,625

-2,443,339

-2,381,182

-2,295,922

-2,212,645

-2,162,351

-2,111,126

-2,045,462

-1,974,061

-1,910,050

-1,857,558

-1,768,610

-1,678,881

-1,617,072

-1,532,521

-1,412,222

-1,334,141

-1,174,978

-1,113,143

-1,063,610

-994,402

-882,737

-834,600

-779,608

-720,961

-674,307

-623,257

-579,566

-536,670

-498,869

-471,736

-447,448

-426,228

-409,079

-394,465

-378,522

-366,285

-351,696

-336,347

-318,889

-308,874

-292,584

-283,241

-270,104

-261,442

-251,683

Accumulated Other Comprehensive Income

0
0
0
0
-2,563
0
0
0
15
17
113
220
408
930
318
68
533
234
145
88
43
2
6
11
-28
1
-14
-25
4
37
17
37
14
15
3
5
1
2
-2
2
-132
-35
-52
-142
-115
49
1,043
1,349
2,047
1,672
-161
-1,468
-2,095
-4,724
-1,994
-1,086
68
-1,152
707
1,280
2,825
6,812
5,153
4,520
8,227
8,835
9,082
6,433
4,981
-1,028
-17,240
-39,078
-12,105
-6,744
4,160
-6,768
5,312

5,312

-6,768

4,160

-6,744

-12,105

-39,078

-17,240

-1,028

4,981

6,433

9,082

8,835

8,227

4,520

5,153

6,812

2,825

1,280

707

-1,152

-1,086

-1,994

-4,724

-2,095

-1,468

-161

1,672

2,047

1,349

1,043

-115

-142

-52

-35

-132

-2

-25

-14

-28

145

234

533

318

930

408

220

113

-2,563

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
295,898
297,849
299,285
363,456
365,210
385,042
387,539
389,113
390,696
392,213
423,593
424,844
444,600
468,650
568,743
574,757
826,582
914,263
917,454
921,234
990,032
1,038,613
1,120,156
1,126,148
1,132,229
1,387,767
1,400,758
1,621,479
1,723,865
1,731,174
1,740,061
1,970,607
2,201,447
2,210,890
2,227,225
2,238,346
2,250,849
2,274,797
2,308,578
2,350,507
2,364,494
2,579,953
2,595,419
2,617,935
2,631,110
2,645,372
2,664,744
2,691,836
2,733,148
0
0

2,733,148

2,691,836

2,664,744

2,645,372

2,631,110

2,617,935

2,595,419

2,579,953

2,364,494

2,350,507

2,308,578

2,274,797

2,250,849

2,238,346

2,227,225

2,210,890

2,201,447

1,970,607

1,740,061

1,731,174

1,723,865

1,621,479

1,400,758

1,387,767

1,132,229

1,126,148

1,120,156

1,038,613

990,032

921,234

917,454

914,263

826,582

574,757

568,743

468,650

444,600

424,844

423,593

392,213

390,696

389,113

387,539

385,042

365,210

363,456

299,285

297,849

295,898

Treasury Stock

Other Stockholders Equity

0
0
0
0
4,015
0
0
0
6,067
6,981
225,027
226,246
227,438
229,035
230,922
232,701
234,412
236,397
238,492
240,499
242,259
257,787
259,266
260,747
290,248
291,696
295,898
297,849
299,285
363,456
365,210
385,042
387,539
389,113
390,696
392,213
423,593
424,844
444,600
468,650
568,743
574,757
826,582
914,263
926,209
933,532
1,006,108
1,054,689
358,104
1,142,224
1,148,305
1,403,843
1,416,834
1,637,555
1,736,928
1,744,237
1,753,124
1,982,994
2,213,834
2,223,277
2,239,612
2,250,733
2,263,236
2,287,184
2,320,965
2,350,507
2,364,494
2,580,036
2,595,502
2,618,018
2,631,193
2,645,455
2,664,827
2,691,919
2,733,219
2,780,578
2,836,018

2,836,018

2,780,578

2,733,219

2,691,919

2,664,827

2,645,455

2,631,193

2,618,018

2,595,502

2,580,036

2,364,494

2,350,507

2,320,965

2,287,184

2,263,236

2,250,733

2,239,612

2,223,277

2,213,834

1,982,994

1,753,124

1,744,237

1,736,928

1,637,555

1,416,834

1,403,843

1,148,305

1,142,224

358,104

1,054,689

1,006,108

933,532

926,209

914,263

826,582

574,757

568,743

468,650

444,600

424,844

423,593

392,213

390,696

389,113

387,539

385,042

365,210

363,456

299,285

297,849

295,898

291,696

290,248

260,747

259,266

257,787

242,259

240,499

238,492

236,397

234,412

232,701

230,922

229,035

227,438

226,246

225,027

6,981

6,067

4,015

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31
Accounts Payable	15,120	15,413	21,513	17,063	120,373	80,625	7,867	41,008	16,477	16,345	2,146	8,845	2,576	1,971	3,837	8,796	530	1,195	906	590	-
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Accumulated Other Comprehensive Income	5,312	-12,105	4,981	8,227	2,825	68	-2,095	2,047	-115	-132	1	14	4	-28	43	533	408	15	-2,563	0	-
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Lease Obligations	57,201	60,130	50,772	52,476	60,720	0	307	283	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Stock	2,918	2,815	2,808	2,650	2,598	1,942	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Capital Surpluse	0	2,664,744	2,595,419	2,308,578	2,227,225	1,740,061	1,400,758	1,120,156	917,454	0	0	387,539	299,285	0	0	0	0	0	0	0	-
Cash	246,994	148,813	245,197	163,240	142,837	79,749	49,060	187,026	69,485	24,074	43,640	33,971	25,668	29,572	19,339	28,073	44,188	12,127	6,449	257	-
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Cash And Short Term Investments	286,200	293,595	482,496	483,269	452,740	504,152	358,562	330,351	214,033	151,675	82,000	99,122	55,702	107,445	78,224	121,124	161,527	54,699	24,418	0	-
Common Stock	2,918	2,815	2,808	2,650	2,598	1,942	1,721	1,480	1,306	1,015	679	556	407	406	287	287	285	70	40	23	-
Common Stock Shares Outstanding	295,165	289,057	271,422	258,867	240,421	185,790	153,355	134,402	109,924	74,444	51,286	45,565	34,570	27,735	22,624	22,494	13,236	736	410	308	308
Common Stock Total Equity	0	2,815	2,808	2,650	2,598	1,942	1,721	1,480	1,306	1,015	679	556	407	406	287	287	285	70	40	0	-
Current Deferred Revenue	12,434	4,939	0	1,500	1,250	0	0	69,403	0	-10,471	0	-6,730	8,504	6,640	0	3,705	3,801	0	0	0	-
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Deferred Long Term Liab	0	9,595	10,836	12,302	13,957	16,621	20,621	195,677	211,975	23,000	0	30,418	18,999	0	0	0	0	0	0	0	-
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Good Will	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	11,613	11,613	0	0	0	0	0	0	0	0	0	-
Intangible Assets	20,490	23,000	23,000	23,000	23,000	23,000	23,000	486,700	486,700	23,000	23,000	0	0	0	0	0	0	0	0	0	-
Inventory	59,696	23,816	26,818	19,556	14,041	8,390	4,623	3,416	0	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities And Stockholders Equity	777,880	724,167	905,140	886,520	850,207	789,951	627,024	1,036,845	908,384	209,967	127,563	110,088	69,795	112,552	85,370	128,773	167,097	59,646	28,670	0	501
Long Term Debt	387,858	391,990	389,357	389,254	149,505	321,740	164,167	154,464	41,601	10,510	14,174	299	0	1,044	2,344	317	1,194	2,256	734	0	-
Long Term Debt Total	0	391,990	389,357	389,254	149,505	321,740	164,167	154,464	41,601	0	0	299	0	0	0	0	0	0	0	0	-
Long Term Investments	0	0	0	0	0	0	0	0	0	17,464	0	0	0	0	0	0	0	0	0	0	-
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Debt	198,065	303,307	194,932	278,490	67,388	241,991	115,414	-32,562	-27,884	-9,724	-29,167	-33,274	-24,624	-27,235	-15,437	-26,879	-41,467	-8,563	-5,436	0	-
Net Invested Capital	548,032	515,037	696,726	675,634	625,930	664,652	517,017	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Receivables	87,632	66,196	52,672	46,923	33,284	21,962	9,464	1,304	0	1,304	759	3,225	5,043	0	0	0	0	0	0	0	-
Net Tangible Assets	0	-97,750	86,572	65,583	255,628	122,112	132,053	-324,346	-336,663	110,565	0	70,128	29,592	0	0	0	0	0	0	0	-
Net Working Capital	315,372	284,798	450,859	449,793	391,261	464,971	321,925	229,105	142,985	134,392	77,817	95,374	47,392	93,458	69,293	110,209	147,247	44,814	22,267	0	-
Non Current Assets Total	294,819	300,351	308,306	307,051	330,134	238,855	235,059	696,781	691,783	55,390	39,285	5,471	3,147	2,871	4,884	5,186	4,057	4,625	3,811	0	-
Non Current Liabilities Other	13,282	60,517	51,603	68,908	81,508	22,553	19,346	215,594	233,358	0	0	0	1,948	0	0	0	0	0	0	0	-
Non Current Liabilities Total	450,017	462,102	451,796	470,464	244,970	360,914	204,134	565,735	486,934	67,604	71,351	31,625	20,947	31,395	2,344	44,352	48,007	126,954	61,907	0	-
Non Currrent Assets Other	15,470	10,001	24,427	19,095	28,317	6,683	5,200	2,468	1,108	502	552	442	709	267	485	267	267	267	532	0	-
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Assets	0	42,242	47,427	65,391	51,317	29,683	28,200	489,168	1,108	502	552	442	709	267	485	267	267	268	532	41	501
Other Current Assets	49,533	40,209	34,848	29,721	20,008	16,592	19,316	4,993	2,568	2,902	5,519	2,270	5,903	2,236	2,262	2,463	1,513	321	441	155	-
Other Current Liab	131,811	110,114	117,053	104,241	1,250	5,500	61,866	265	57,139	10,471	8,016	6,730	7,132	8,290	9,635	10,514	9,935	7,704	1,407	158	-
Other Liab	0	18,534	19,076	35,606	41,934	39,174	39,967	411,271	445,333	47,908	47,991	31,326	20,947	30,351	0	44,035	46,813	609	704	0	-
Other Stockholder Equity	2,836,018	2,664,827	2,595,502	2,320,965	2,239,612	1,753,124	1,416,834	358,104	926,209	568,743	423,593	387,539	299,285	290,248	242,259	234,412	227,438	6,067	4,015	0	3,228
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	124,089	60,469	20,014	-
Property Plant And Equipment Gross	83,408	82,593	82,964	67,159	81,020	11,375	9,062	9,816	6,178	2,811	4,120	5,029	2,438	2,604	4,399	4,919	3,790	4,358	3,279	0	-
Property Plant And Equipment Net	57,979	60,312	63,082	67,159	81,020	11,375	9,062	9,816	6,178	2,811	4,120	5,029	2,438	2,604	4,399	4,919	3,790	4,358	3,279	0	-
Property Plant Equipment	0	30,778	42,496	43,863	47,705	11,375	9,062	9,816	6,178	2,811	4,120	5,029	2,438	2,604	4,399	4,919	3,790	4,358	3,279	541	-
Retained Earnings	-2,684,074	-2,532,490	-2,295,922	-2,045,462	-1,768,610	-1,412,222	-1,063,610	-779,608	-579,566	-447,448	-378,522	-318,889	-270,104	-225,692	-170,756	-164,189	-124,834	-83,667	-37,322	0	-8,503
Retained Earnings Total Equity	0	-2,532,490	-2,295,922	-2,045,462	-1,768,610	-1,412,222	-1,063,610	-779,608	-579,566	0	0	-318,889	-270,104	0	0	0	0	0	0	0	-
Short Long Term Debt	0	0	0	0	0	0	164,474	154,747	41,601	3,840	0	0	0	0	0	0	0	0	0	0	-
Short Long Term Debt Total	445,059	452,120	440,129	441,730	210,225	321,740	164,474	154,464	41,601	14,350	14,473	697	1,044	2,337	3,902	1,194	2,721	3,564	1,014	0	-
Short Term Debt	8,324	8,552	7,409	6,872	7,189	0	307	283	41,601	3,840	299	398	1,044	1,293	1,558	877	1,527	1,307	279	0	-
Short Term Investments	39,206	144,782	237,299	320,029	309,903	424,403	309,502	143,325	144,548	127,601	38,360	65,151	30,034	77,873	58,885	93,051	117,339	42,572	17,969	4,079	-
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Assets	777,880	724,167	905,140	886,520	850,207	789,951	627,024	1,036,845	908,384	209,967	127,563	110,088	69,795	112,552	85,370	128,773	167,097	59,646	28,670	5,073	501
Total Current Assets	483,061	423,816	596,834	579,469	520,073	551,096	391,965	340,064	216,601	154,577	88,278	104,617	66,648	109,681	80,486	123,587	163,040	55,020	24,859	0	-
Total Current Liabilities	167,689	139,018	145,975	129,676	128,812	86,125	70,040	110,959	73,616	20,185	10,461	9,243	19,256	16,223	11,193	13,378	15,793	10,207	2,593	922	-
Total Liab	617,706	601,120	597,771	600,140	373,782	447,039	274,174	676,694	560,550	87,789	81,812	40,868	40,203	47,618	13,537	57,730	63,800	137,161	64,500	922	5,776
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Stockholder Equity	160,174	123,047	307,369	286,380	476,425	342,912	352,850	360,151	347,834	122,178	45,751	69,220	29,592	64,934	71,833	71,043	103,297	-77,515	-35,830	4,151	-5,275
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Warrants	0	83	83	12,387	12,387	13,063	16,076	16,076	8,755	0	0	908	0	0	0	0	0	0	0	0	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31
Accounts Payable	15,120	23,154	13,522	24,965	15,413	12,046	23,113	22,914	21,513	24,474	13,762	16,110	17,063	14,764	14,306	16,239	120,373	81,475	84,119	60,596	6,606	54,330	41,613	43,678	7,867	53,709	35,645	39,645	12,905	29,013	23,828	22,501	16,477	30,565	16,901	15,833	16,345	11,331	9,918	9,167	2,146	8,166	9,018	6,427	8,845	9,428	9,067	8,449	2,576	8,098	7,019	7,418	1,971	6,809	5,752	7,358	3,837	12,759	10,988	8,683	8,796	9,804	10,745	1,050	530	535	338	1,738	1,195	-	-	-	906	-	-	-	590
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Accumulated Other Comprehensive Income	5,312	-6,768	4,160	-6,744	-12,105	-39,078	-17,240	-1,028	4,981	6,433	9,082	8,835	8,227	4,520	5,153	6,812	2,825	1,280	707	-1,152	68	-1,086	-1,994	-4,724	-2,095	-1,468	-161	1,672	2,047	1,349	1,043	49	-115	-142	-52	-35	-132	2	-2	2	1	5	3	15	14	37	17	37	4	-25	-14	1	-28	11	6	2	43	88	145	234	533	68	318	930	408	220	113	17	15	-	-	-	-2,563	-	-	-	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Capital Lease Obligations	57,201	60,219	58,816	59,354	60,130	59,548	60,387	57,712	50,772	50,670	51,307	51,195	52,476	51,995	52,182	60,025	60,720	56,042	38,937	38,623	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Capital Stock	2,918	2,890	2,856	2,820	2,815	2,813	2,811	2,809	2,808	2,805	2,685	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Capital Surpluse	0	0	2,733,148	2,691,836	2,664,744	2,645,372	2,631,110	2,617,935	2,595,419	2,579,953	2,364,494	2,350,507	2,308,578	2,274,797	2,250,849	2,238,346	2,227,225	2,210,890	2,201,447	1,970,607	1,740,061	1,731,174	1,723,865	1,621,479	1,400,758	1,387,767	1,132,229	1,126,148	1,120,156	1,038,613	990,032	921,234	917,454	914,263	826,582	574,757	568,743	468,650	444,600	424,844	423,593	392,213	390,696	389,113	387,539	385,042	365,210	363,456	299,285	297,849	295,898	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Cash	246,994	263,320	211,307	160,602	148,813	277,592	235,639	233,317	245,197	385,903	176,538	184,833	163,240	210,631	164,573	123,231	142,837	166,319	220,578	96,349	79,749	201,827	73,311	114,322	49,060	64,133	37,394	44,755	187,026	33,115	63,656	23,510	69,485	19,439	249,023	28,827	24,074	19,671	41,904	27,533	43,640	30,047	23,476	26,736	33,971	24,273	28,858	24,523	25,668	22,810	25,789	27,662	29,572	22,097	24,622	33,562	19,339	20,487	15,760	23,242	28,073	19,855	12,315	18,203	44,188	19,933	26,494	19,853	12,127	-	-	-	6,449	-	-	-	257
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Cash And Short Term Investments	286,200	280,300	265,626	267,109	293,595	354,700	386,841	411,195	482,496	556,960	383,068	417,429	483,269	509,082	309,590	338,873	452,740	514,194	575,656	438,327	504,152	564,383	538,952	562,520	358,562	411,521	227,232	279,842	330,351	212,399	214,150	165,851	214,033	236,509	361,419	148,767	151,675	85,182	77,996	71,654	82,000	60,495	74,176	84,751	99,122	106,215	95,772	108,196	55,702	69,528	83,046	93,774	107,445	57,581	69,066	81,432	78,224	89,271	100,430	109,048	121,124	136,255	144,950	154,558	161,527	119,408	125,723	67,706	54,699	-	-	-	24,418	-	-	-	0
Common Stock	2,918	2,890	2,856	2,820	2,815	2,813	2,811	2,809	2,808	2,805	2,685	2,680	2,650	2,626	2,614	2,607	2,598	2,591	2,589	2,347	1,942	1,941	1,939	1,929	1,721	1,707	1,485	1,482	1,480	1,478	1,399	1,308	1,306	1,304	1,241	1,024	1,015	853	789	703	679	556	556	556	556	554	524	524	407	407	406	406	406	337	337	337	287	287	287	287	287	285	285	285	285	284	283	82	70	-	-	-	40	-	-	-	23
Common Stock Shares Outstanding	293,594	295,759	292,797	291,337	281,108	289,224	291,971	288,482	267,465	267,465	266,399	264,369	259,162	259,162	257,973	256,968	256,968	254,674	238,090	213,519	213,519	189,163	188,621	175,978	160,797	160,797	143,001	142,771	134,402	140,656	129,122	125,179	125,179	118,725	99,994	95,743	86,952	78,889	67,213	64,354	64,354	49,621	49,621	49,621	49,478	48,514	46,870	37,888	37,888	34,980	34,531	34,499	34,499	27,625	27,623	24,289	24,289	22,622	22,618	22,614	22,614	22,517	22,467	22,413	22,413	22,292	7,084	954	736	736	736	736	410	410	410	410	0
Common Stock Total Equity	0	0	2,856	2,820	2,815	2,813	2,811	2,809	2,808	2,805	2,685	2,680	2,650	2,626	2,614	2,607	2,598	2,591	2,589	2,347	1,942	1,941	1,939	1,929	1,721	1,707	1,485	1,482	1,480	1,478	1,399	1,308	1,306	1,304	1,241	1,024	1,015	853	789	703	679	556	556	556	556	554	524	524	407	407	406	406	406	337	337	337	287	287	287	287	287	285	285	285	285	284	283	82	70	-	-	-	40	-	-	-	0
Current Deferred Revenue	12,434	0	0	0	4,939	4,930	4,930	0	4,930	0	0	0	4,896	5,051	0	0	5,051	0	0	0	0	0	0	0	0	0	0	0	97,506	0	0	0	0	0	0	-21,022	-10,471	-13,824	-11,171	-9,366	0	0	0	0	-6,730	0	7,929	8,187	8,504	9,274	8,606	7,965	6,640	0	0	0	0	2,778	2,778	3,176	3,705	4,043	3,295	4,612	3,801	0	0	0	0	-	-	-	0	-	-	-	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Deferred Long Term Liab	0	0	5,906	5,906	9,595	10,836	23,000	5,906	10,836	12,302	23,000	12,302	12,302	13,957	13,957	13,957	13,957	15,371	17,871	17,871	16,621	20,621	20,621	20,621	20,621	26,092	190,775	195,726	195,677	211,975	211,975	211,975	211,975	243,833	45,806	45,806	45,806	45,863	45,863	45,863	45,863	34,019	32,709	31,685	30,418	27,235	15,679	17,339	18,999	20,659	22,319	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Good Will	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	197,797	207,564	11,613	11,613	11,613	11,613	11,613	11,613	11,613	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Intangible Assets	20,490	21,318	22,145	22,964	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	23,000	486,700	486,700	486,700	486,700	486,700	486,700	486,700	518,810	23,000	23,000	23,000	23,000	23,000	23,000	23,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Inventory	59,696	56,936	51,381	27,004	23,816	13,272	20,879	24,324	26,818	22,072	24,086	18,801	19,556	15,767	12,979	12,831	14,041	9,154	10,395	8,167	8,390	6,311	7,769	8,070	4,623	7,272	3,948	3,698	3,416	3,251	194	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Liabilities And Stockholders Equity	777,880	764,084	730,093	700,519	724,167	759,528	800,589	826,938	905,140	956,675	786,892	810,034	886,520	900,542	701,451	738,349	850,207	882,292	918,033	764,702	789,951	838,589	825,889	870,005	627,024	680,779	938,966	993,381	1,036,845	918,180	914,006	862,907	908,384	986,692	403,913	192,616	209,967	125,487	117,994	112,357	127,563	69,106	82,335	93,216	110,088	118,211	111,598	120,801	69,795	78,867	90,288	102,551	112,552	63,762	74,886	88,137	85,370	98,892	108,676	116,375	128,773	143,165	151,083	159,532	167,097	124,833	131,583	73,048	59,646	-	-	-	28,670	-	-	-	0
Long Term Debt	387,858	394,071	393,350	392,658	391,990	391,319	390,652	389,994	389,357	388,719	390,434	389,789	389,254	388,584	150,037	149,736	149,505	149,260	149,064	168,818	321,740	318,808	169,440	166,768	164,167	161,635	159,171	156,859	154,464	21,977	21,851	38,509	41,601	50,000	0	9,208	10,510	11,809	13,104	14,216	14,174	0	100	199	299	398	498	597	0	104	418	731	1,044	1,357	1,670	2,007	2,344	2,696	2,151	223	317	483	695	918	1,194	1,573	1,953	1,907	2,256	-	-	-	734	-	-	-	0
Long Term Debt Total	0	0	393,350	392,658	391,990	391,319	0	0	389,357	388,719	390,434	389,789	389,254	388,584	150,037	149,736	149,505	149,260	149,064	168,818	321,740	318,808	169,440	166,768	164,167	161,635	159,171	156,859	154,464	21,977	21,851	38,509	41,601	0	0	9,208	10,510	11,809	13,104	14,216	14,174	0	100	199	299	398	498	597	0	104	418	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13,836	42,673	0	15,109	0	0	0	0	0	0	0	15,428	0	2,804	17,464	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Net Debt	198,065	190,970	240,859	291,410	303,307	173,275	215,400	214,389	194,932	53,486	265,203	256,151	278,490	229,948	37,646	86,530	67,388	38,983	-32,577	111,092	241,991	116,981	96,129	52,446	115,414	97,502	121,777	112,104	-32,279	32,909	1,638	14,999	-27,884	30,561	-249,023	-14,430	-9,724	-5,369	-27,547	-13,118	-29,167	-29,649	-22,978	-26,139	-33,274	-23,373	-27,544	-22,797	-24,624	-21,453	-24,118	-25,678	-27,235	-19,401	-21,557	-30,075	-15,437	-16,246	-13,006	-22,324	-26,879	-18,282	-10,362	-15,865	-41,467	-16,839	-23,037	-16,604	-8,563	-	-	-	-5,436	-	-	-	0
Net Invested Capital	548,032	527,308	504,931	495,231	515,037	523,884	564,077	628,611	696,726	765,348	604,344	640,685	675,634	708,853	510,990	552,330	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Net Receivables	87,632	73,331	63,716	68,178	66,196	52,303	52,556	52,421	52,672	51,427	49,172	44,931	46,923	44,828	43,040	40,555	33,284	33,731	28,709	22,960	21,962	14,189	15,077	10,836	9,464	5,974	3,786	1,875	1,304	864	864	0	1,304	0	0	0	1,304	293	475	38	759	2,121	1,024	1,308	3,225	3,184	7,237	4,301	5,043	3,828	1,977	3,969	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Net Tangible Assets	0	-85,878	-108,361	-118,188	-97,750	-88,232	-24,372	17,820	86,572	155,832	16,113	30,099	65,583	99,472	140,156	181,797	255,628	327,470	379,261	230,871	122,112	190,154	341,098	300,820	132,053	188,883	-417,605	-373,719	-324,346	-347,942	-350,254	-372,865	-336,663	-297,619	294,289	69,397	87,565	8,664	1,695	-3,529	11,138	26,489	39,559	53,337	70,128	80,648	77,609	80,776	29,592	36,789	44,607	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Net Working Capital	315,372	293,802	273,587	261,312	284,798	293,889	333,018	389,201	450,859	529,438	368,509	403,239	449,793	473,550	275,584	316,235	391,261	483,576	545,329	417,177	464,971	535,154	523,267	451,328	321,925	362,854	140,306	186,611	229,105	136,100	137,215	104,086	142,985	204,188	348,096	130,229	134,392	73,413	68,251	64,084	77,817	55,710	67,211	79,817	95,374	102,546	87,855	97,521	47,392	57,769	71,221	83,411	93,458	52,330	64,000	75,098	69,293	76,494	87,846	98,478	110,209	123,308	131,323	140,824	147,247	111,082	120,190	59,526	44,814	-	-	-	22,267	-	-	-	0
Non Current Assets Total	294,819	300,828	297,271	300,822	300,351	300,989	302,946	308,038	308,306	306,135	306,390	307,143	307,051	315,265	317,567	330,400	330,134	305,635	283,157	281,656	238,855	237,555	249,659	277,972	235,059	249,766	697,977	697,174	696,781	696,468	696,332	694,394	691,783	746,639	38,916	41,365	55,390	38,250	38,572	38,907	39,285	4,798	5,157	5,404	5,471	5,735	5,931	5,515	3,147	2,473	2,189	2,504	2,871	3,284	3,739	4,201	4,884	5,316	5,593	5,343	5,186	4,920	4,462	3,898	4,057	4,180	4,428	4,955	4,625	-	-	-	3,811	-	-	-	0
Non Current Liabilities Other	13,282	8,962	60,021	60,997	60,517	60,158	8,207	7,335	51,603	57,923	6,535	57,395	68,908	66,005	68,204	80,348	81,508	76,313	61,493	60,476	22,553	22,329	20,970	20,294	19,346	15,213	221,445	220,422	215,594	262,061	265,478	236,364	233,358	278,239	12,304	12,570	11,288	10,714	11,548	11,828	11,314	0	0	0	0	0	0	4,324	1,948	2,690	6,066	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Non Current Liabilities Total	450,017	461,393	459,277	459,561	462,102	462,313	462,539	458,622	451,796	458,944	460,989	459,486	470,464	468,546	232,198	244,041	244,970	240,944	228,428	247,165	360,914	361,758	211,031	207,683	204,134	202,940	571,391	573,007	565,735	496,013	499,304	486,848	486,934	572,072	58,110	67,584	67,604	68,386	70,515	71,907	71,351	34,019	32,809	31,884	31,625	31,522	20,619	22,260	20,947	23,453	28,803	32,854	31,395	5,123	3,377	5,105	2,344	44,648	44,798	43,564	44,352	45,213	46,119	47,037	48,007	1,573	1,953	150,763	126,954	-	-	-	61,907	-	-	-	0
Non Currrent Assets Other	15,470	21,130	19,049	20,172	19,242	9,001	8,893	25,188	24,427	22,077	21,200	20,538	19,095	-277,049	25,876	29,414	28,317	14,351	12,035	11,265	6,683	6,099	-550	-873	5,200	-4,967	3,009	2,932	2,468	1,788	1,657	1,484	1,108	982	924	892	502	508	515	546	552	442	442	442	442	442	442	442	709	714	267	267	267	267	267	267	485	267	267	267	267	504	267	267	267	267	267	690	267	-	-	-	532	-	-	-	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Other Assets	0	21,130	19,049	20,172	42,242	40,872	41,045	48,188	47,427	45,077	44,200	43,538	65,391	49,453	48,876	52,414	51,317	37,351	35,035	11,265	29,683	29,099	28,915	28,592	225,997	240,125	687,506	687,429	686,965	686,285	686,154	685,981	685,605	742,784	35,537	38,309	52,579	35,121	35,128	35,159	35,165	442	442	442	442	442	442	442	709	714	267	267	267	267	267	267	485	267	267	267	267	504	267	267	267	267	267	690	268	-	-	-	532	-	-	-	41
Other Current Assets	49,533	52,689	52,099	37,406	40,209	38,264	37,367	30,960	34,848	20,081	24,176	21,730	29,721	15,600	18,275	15,690	20,008	19,578	20,116	13,592	16,592	16,151	14,432	10,607	19,316	6,246	6,023	10,792	4,993	5,198	3,330	2,662	2,568	3,544	3,578	2,484	2,902	1,762	951	1,758	5,519	1,692	1,978	1,753	2,270	3,077	2,658	2,789	5,903	3,038	3,076	2,304	2,236	2,897	2,081	2,504	2,262	4,305	2,653	1,984	2,463	1,990	1,671	1,076	1,513	1,245	1,432	-1	321	-	-	-	441	-	-	-	155
Other Current Liab	131,811	138,535	137,873	105,415	110,114	140,138	129,039	99,530	112,123	89,453	91,125	76,778	100,845	84,544	85,478	67,972	-3,801	5,250	2,750	2,750	79,519	11,550	11,350	97,027	61,866	14,450	65,038	69,951	265	56,599	56,631	41,926	57,139	5,300	0	21,022	10,471	13,824	11,171	9,366	8,016	34	551	1,170	6,730	9,428	9,067	8,449	7,132	8,098	7,019	7,418	8,290	6,809	5,752	7,358	9,635	12,759	868	8,683	10,514	4,043	3,295	7,728	9,935	7,515	5,123	5,487	7,704	-	-	-	1,407	-	-	-	158
Other Liab	0	14,868	14,951	0	18,534	18,982	19,043	18,171	19,076	26,730	26,354	25,266	35,606	35,335	38,495	41,783	41,934	41,998	43,105	42,247	39,037	42,950	41,591	40,915	33,502	32,119	238,351	242,328	237,500	253,770	257,791	272,120	269,114	314,859	48,924	49,190	47,908	47,391	48,225	48,505	47,991	34,019	32,709	31,685	31,326	31,124	20,121	21,663	20,947	23,349	28,385	32,123	30,351	3,766	1,707	3,098	0	41,952	42,647	43,341	44,035	44,730	45,424	46,119	46,813	0	0	672	609	-	-	-	704	-	-	-	0
Other Stockholder Equity	2,836,018	2,780,578	2,733,219	2,691,919	2,664,827	2,645,455	2,631,193	2,618,018	2,595,502	2,580,036	2,364,494	2,350,507	2,320,965	2,287,184	2,263,236	2,250,733	2,239,612	2,223,277	2,213,834	1,982,994	1,753,124	1,744,237	1,736,928	1,637,555	1,416,834	1,403,843	1,148,305	1,142,224	358,104	1,054,689	1,006,108	933,532	926,209	914,263	826,582	574,757	568,743	468,650	444,600	424,844	423,593	392,213	390,696	389,113	387,539	385,042	365,210	363,456	299,285	297,849	295,898	291,696	290,248	260,747	259,266	257,787	242,259	240,499	238,492	236,397	234,412	232,701	230,922	229,035	227,438	226,246	225,027	6,981	6,067	-	-	-	4,015	-	-	-	0
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	148,184	124,089	-	-	-	60,469	-	-	-	20,014
Property Plant And Equipment Gross	83,408	85,601	82,340	82,790	82,593	85,657	0	0	0	0	64,393	65,808	67,159	68,015	70,894	80,189	81,020	70,487	50,325	49,594	11,375	10,659	9,111	8,910	9,062	9,641	10,471	9,745	9,816	10,183	10,178	8,413	6,178	3,855	3,379	3,056	2,811	3,129	3,444	3,748	4,120	4,356	4,715	4,962	5,029	5,293	5,489	5,073	2,438	1,759	1,922	2,237	2,604	3,017	3,472	3,934	4,399	5,049	5,326	5,076	4,919	4,416	4,195	3,631	3,790	3,913	4,161	4,265	4,358	-	-	-	3,279	-	-	-	0
Property Plant And Equipment Net	57,979	60,583	58,280	59,889	60,312	62,320	64,104	62,053	63,082	63,261	64,393	65,808	67,159	68,015	70,894	80,189	81,020	70,487	50,325	49,594	11,375	10,659	9,111	8,910	9,062	9,641	10,471	9,745	9,816	10,183	10,178	8,413	6,178	3,855	3,379	3,056	2,811	3,129	3,444	3,748	4,120	4,356	4,715	4,962	5,029	5,293	5,489	5,073	2,438	1,759	1,922	2,237	2,604	3,017	3,472	3,934	4,399	5,049	5,326	5,076	4,919	4,416	4,195	3,631	3,790	3,913	4,161	4,265	4,358	-	-	-	3,279	-	-	-	0
Property Plant Equipment	0	60,583	30,238	31,406	30,778	32,449	64,104	34,544	42,496	41,991	64,393	43,445	43,863	44,618	46,945	47,688	47,705	34,673	15,273	13,286	11,375	10,659	9,111	8,910	9,062	9,641	10,471	9,745	9,816	10,183	10,178	8,413	6,178	3,855	3,379	3,056	2,811	3,129	3,444	3,748	4,120	4,356	4,715	4,962	5,029	5,293	5,489	5,073	2,438	1,759	1,922	2,237	2,604	3,017	3,472	3,934	4,399	5,049	5,326	5,076	4,919	4,416	4,195	3,631	3,790	3,913	4,161	4,265	4,358	-	-	-	3,279	-	-	-	541
Retained Earnings	-2,684,074	-2,650,231	-2,628,654	-2,585,422	-2,532,490	-2,476,625	-2,443,339	-2,381,182	-2,295,922	-2,212,645	-2,162,351	-2,111,126	-2,045,462	-1,974,061	-1,910,050	-1,857,558	-1,768,610	-1,678,881	-1,617,072	-1,532,521	-1,412,222	-1,334,141	-1,174,978	-1,113,143	-1,063,610	-994,402	-882,737	-834,600	-779,608	-720,961	-674,307	-623,257	-579,566	-536,670	-498,869	-471,736	-447,448	-426,228	-409,079	-394,465	-378,522	-366,285	-351,696	-336,347	-318,889	-308,874	-292,584	-283,241	-270,104	-261,442	-251,683	-239,042	-225,692	-210,604	-195,247	-183,932	-170,756	-203,712	-190,283	-176,661	-164,189	-150,039	-141,859	-132,565	-124,834	-113,061	-102,758	-93,362	-83,667	-	-	-	-37,322	-	-	-	0
Retained Earnings Total Equity	0	0	-2,628,654	-2,585,422	-2,532,490	-2,476,625	-2,443,339	-2,381,182	-2,295,922	-2,212,645	-2,162,351	-2,111,126	-2,045,462	-1,974,061	-1,910,050	-1,857,558	-1,768,610	-1,678,881	-1,617,072	-1,532,521	-1,412,222	-1,334,141	-1,174,978	-1,113,143	-1,063,610	-994,402	-882,737	-834,600	-779,608	-720,961	-674,307	-623,257	-579,566	-536,670	-498,869	-471,736	-447,448	-426,228	-409,079	-394,465	-378,522	-366,285	-351,696	-336,347	-318,889	-308,874	-292,584	-283,241	-270,104	-261,442	-251,683	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,421	0	0	169,440	166,768	164,474	161,635	159,171	56,101	154,747	55,992	56,000	0	41,601	0	0	0	3,840	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Short Long Term Debt Total	445,059	454,290	452,166	452,012	452,120	450,867	451,039	447,706	440,129	439,389	441,741	440,984	441,730	440,579	202,219	209,761	210,225	205,302	188,001	207,441	321,740	318,808	169,440	166,768	164,474	161,635	159,171	156,859	154,747	66,024	65,294	38,509	41,601	50,000	0	14,397	14,350	14,302	14,357	14,415	14,473	398	498	597	697	900	1,314	1,726	1,044	1,357	1,671	1,984	2,337	2,696	3,065	3,487	3,902	4,241	2,754	918	1,194	1,573	1,953	2,338	2,721	3,094	3,457	3,249	3,564	-	-	-	1,014	-	-	-	0
Short Term Debt	8,324	7,765	7,840	8,005	8,552	7,536	7,543	7,255	7,409	7,175	7,106	6,764	6,872	7,368	8,516	7,503	7,189	6,356	2,678	2,523	0	0	169,440	80,577	307	161,635	159,171	56,101	283	55,992	56,000	0	41,601	0	0	5,189	3,840	2,493	1,253	199	299	398	398	398	398	502	816	1,129	1,044	1,253	1,253	1,253	1,293	1,339	1,395	1,480	1,558	1,545	603	695	877	1,090	1,258	1,420	1,527	1,521	1,504	1,342	1,307	-	-	-	279	-	-	-	0
Short Term Investments	39,206	16,980	54,319	106,507	144,782	77,108	151,202	177,878	237,299	171,057	206,530	232,596	320,029	298,451	145,017	215,642	309,903	347,875	355,078	341,978	424,403	362,556	465,641	448,198	309,502	347,388	189,838	235,087	143,325	179,284	150,494	142,341	144,548	217,070	112,396	119,940	127,601	65,511	36,092	44,121	38,360	30,448	50,700	58,015	65,151	81,942	66,914	83,673	30,034	46,718	57,257	66,112	77,873	35,484	44,444	47,870	58,885	68,784	84,670	85,806	93,051	116,400	132,635	136,355	117,339	99,475	99,229	47,853	42,572	-	-	-	17,969	-	-	-	4,079
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Total Assets	777,880	764,084	730,093	700,519	724,167	759,528	800,589	826,938	905,140	956,675	786,892	810,034	886,520	900,542	701,451	738,349	850,207	882,292	918,033	764,702	789,951	838,589	825,889	870,005	627,024	680,779	938,966	993,381	1,036,845	918,180	914,006	862,907	908,384	986,692	403,913	192,616	209,967	125,487	117,994	112,357	127,563	69,106	82,335	93,216	110,088	118,211	111,598	120,801	69,795	78,867	90,288	102,551	112,552	63,762	74,886	88,137	85,370	98,892	108,676	116,375	128,773	143,165	151,083	159,532	167,097	124,833	131,583	73,048	59,646	-	-	-	28,670	-	-	-	5,073
Total Current Assets	483,061	463,256	432,822	399,697	423,816	458,539	497,643	518,900	596,834	650,540	480,502	502,891	579,469	585,277	383,884	407,949	520,073	576,657	634,876	483,046	551,096	601,034	576,230	592,033	391,965	431,013	240,989	296,207	340,064	221,712	217,674	168,513	216,601	240,053	364,997	151,251	154,577	87,237	79,422	73,450	88,278	64,308	77,178	87,812	104,617	112,476	105,667	115,286	66,648	76,394	88,099	100,047	109,681	60,478	71,147	83,936	80,486	93,576	103,083	111,032	123,587	138,245	146,621	155,634	163,040	120,653	127,155	68,093	55,020	-	-	-	24,859	-	-	-	0
Total Current Liabilities	167,689	169,454	159,235	138,385	139,018	164,650	164,625	129,699	145,975	121,102	111,993	99,652	129,676	111,727	108,300	91,714	128,812	93,081	89,547	65,869	86,125	65,880	52,963	140,705	70,040	68,159	100,683	109,596	110,959	85,612	80,459	64,427	73,616	35,865	16,901	21,022	20,185	13,824	11,171	9,366	10,461	8,598	9,967	7,995	9,243	9,930	17,812	17,765	19,256	18,625	16,878	16,636	16,223	8,148	7,147	8,838	11,193	17,082	15,237	12,554	13,378	14,937	15,298	14,810	15,793	9,571	6,965	8,567	10,207	-	-	-	2,593	-	-	-	922
Total Liab	617,706	630,847	618,512	597,946	601,120	626,963	627,164	588,321	597,771	580,046	572,982	559,138	600,140	580,273	340,498	335,755	373,782	334,025	317,975	313,034	447,039	427,638	263,994	348,388	274,174	271,099	672,074	682,603	676,694	581,625	579,763	551,275	560,550	607,937	75,011	88,606	87,789	82,210	81,686	81,273	81,812	42,617	42,776	39,879	40,868	41,452	38,431	40,025	40,203	42,078	45,681	49,490	47,618	13,271	10,524	13,943	13,537	61,730	60,035	56,118	57,730	60,150	61,417	61,847	63,800	11,144	8,918	159,330	137,161	-	-	-	64,500	-	-	-	922
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Total Stockholder Equity	160,174	133,237	111,581	102,573	123,047	132,565	173,425	238,617	307,369	376,629	213,910	250,896	286,380	320,269	360,953	402,594	476,425	548,267	600,058	451,668	342,912	410,951	561,895	521,617	352,850	409,680	266,892	310,778	360,151	336,555	334,243	311,632	347,834	378,755	328,902	104,010	122,178	43,277	36,308	31,084	45,751	26,489	39,559	53,337	69,220	76,759	73,167	80,776	29,592	36,789	44,607	53,061	64,934	50,491	64,362	74,194	71,833	37,162	48,641	60,257	71,043	83,015	89,666	97,685	103,297	113,689	122,665	-86,282	-77,515	-	-	-	-35,830	-	-	-	4,151
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Warrants	0	0	71	83	83	83	83	83	83	83	0	0	12,387	12,387	12,387	12,387	12,387	12,387	12,387	12,387	13,063	13,063	13,063	16,076	16,076	16,076	16,076	16,076	16,076	16,076	16,076	12,298	8,755	0	0	0	0	0	0	0	0	0	0	0	908	3,889	4,442	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Begin Period Cash Flow	148,813	249,456	166,162	146,343	82,375	51,237	187,026	69,485	24,074	43,640	33,971	25,668	29,572	19,339	28,073	44,188	12,127	6,449	257	0
Capital Expenditures	7,440	3,766	3,884	3,227	20,012	6,308	4,526	5,951	4,817	238	695	4,324	1,420	384	1,807	2,667	669	2,031	3,040	228
Cash And Cash Equivalents Changes	0	-81,722	88,343	15,989	62,239	29,620	-137,966	117,541	45,411	-19,566	9,669	8,303	-3,904	0	0	0	0	0	0	0
Cash Flows Other Operating	0	13,468	-16,824	-280	-20,065	1,613	-197,298	-61	-358	2,319	-3,249	3,247	-6,873	0	0	0	0	0	0	0
Change In Cash	98,181	-96,341	83,294	19,819	63,968	31,138	-137,966	117,541	45,411	-19,566	9,669	8,303	-3,904	10,233	-8,734	-16,115	32,061	5,677	6,192	0
Change In Working Capital	-47,990	-39,880	-18,585	-32,064	11,610	-4,727	-25,787	1,135	14,338	9,388	4,863	7,770	-12,510	31,178	-46,918	-5,491	50,988	6,970	789	0
Change Receivables	0	-17,330	-8,189	-11,219	-11,114	-13,294	-7,725	-1,419	0	1,083	2,466	1,818	-5,043	0	0	0	0	0	0	0
Change To Account Receivables	-20,108	-17,330	-8,189	-11,219	-11,114	-13,294	-7,725	-1,419	-1,419	1,083	2,466	1,818	0	0	0	0	0	0	0	0
Change To Inventory	-44,614	-5,343	-7,790	-4,639	-5,114	-4,205	-897	-3,651	-3,651	2,293	-3,249	3,633	0	0	0	0	0	0	0	0
Change To Liabilities	0	-6,377	7,430	-10,610	46,742	17,115	12,563	7,131	14,696	6,169	5,646	2,052	-3,358	0	839	0	1,566	6,586	1,566	0
Change To Netincome	0	77,599	64,643	59,670	88,202	32,619	258,281	44,266	15,808	6,322	7,257	6,219	8,679	0	0	0	0	0	0	0
Change To Operating Activities	0	-10,830	-18,889	-4,346	-13,404	1,907	-15,338	-539	-265	2,193	0	0	0	0	0	0	0	0	0	0
Depreciation	7,873	5,342	6,209	8,846	4,775	4,216	3,593	3,242	1,833	1,547	1,719	1,705	1,585	2,058	2,132	1,493	1,237	952	667	0
Dividends Paid	0	-4,310	-15,009	-32,254	3,235	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	246,994	153,115	249,456	166,162	146,343	82,375	49,060	187,026	69,485	24,074	43,640	33,971	25,668	29,572	19,339	28,073	44,188	12,127	6,449	257
Exchange Rate Changes	0	0	0	0	0	0	1,326	-131	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-76,531	-170,341	-206,375	-236,517	-270,428	-306,263	-220,011	-156,485	-104,956	-51,907	-46,489	-38,068	-50,842	-14,367	-45,178	-39,530	14,523	-35,920	-21,165	0
Investments	55,317	92,671	82,645	-10,352	115,165	-114,892	-166,715	1,442	534	-106,838	26,778	-35,107	47,872	0	0	0	0	0	0	0
Issuance Of Capital Stock	63,108	2,354	199,750	0	188,994	294,584	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-283	-479	230,680	-420	146,262	-308	192,343	34,709	-299	14,380	-347	-1,293	0	0	0	0	0	0	0
Net Income	-151,584	-236,568	-250,460	-276,852	-356,388	-348,995	-284,002	-200,042	-132,118	-68,926	-59,633	-48,785	-44,412	-54,936	-6,567	-39,355	-41,167	-46,345	-19,972	0
Other Cashflows From Financing Activities	-20,573	4,310	42,820	418,183	35,398	156,525	4,705	255,840	63,142	3,673	14,778	2,625	-44,855	9	3,818	-1,528	-842	2,550	839	0
Other Cashflows From Investing Activities	0	3,411	0	0	115,165	-114,892	-166,715	1,442	-141,060	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	41,472	28,010	2,473	17,784	46,572	14,276	234,915	31,369	4,884	314	1,988	-625	-2,764	1,410	195	6,446	4,134	4,534	392	0
Sale Purchase Of Stock	0	-11,490	-15,009	-10,028	-3,235	307,345	259,338	100,104	258,228	135,805	15,000	81,825	359	0	0	0	0	0	0	0
Stock Based Compensation	86,077	76,512	57,838	49,151	44,430	29,260	23,101	17,504	9,972	6,008	6,177	6,191	8,679	6,186	7,787	6,446	2,816	0	0	0
Total Cash From Financing Activities	61,677	-7,463	212,073	262,858	217,502	450,775	247,434	272,715	290,893	139,179	29,380	81,478	-934	43,658	2,769	-998	91,911	66,170	41,254	13,906
Total Cash From Operating Activities	-69,091	-166,575	-202,491	-233,290	-250,416	-299,955	-215,485	-150,534	-100,139	-51,669	-45,794	-33,744	-49,422	-13,983	-43,371	-36,863	15,192	-33,889	-18,124	0
Total Cashflows From Investing Activities	0	92,316	78,761	-13,579	95,153	-121,200	-171,241	-4,509	-145,343	-107,076	26,083	-39,431	46,452	0	31,868	21,746	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2005-12-31	2004-12-31
Begin Period Cash Flow	263,320	214,333	164,983	153,115	281,533	239,861	237,823	249,456	389,071	179,788	188,049	166,162	213,425	167,262	125,893	146,341	169,701	223,188	98,928	82,375	203,830	75,441	116,552	51,237	64,133	37,394	44,755	187,026	33,115	63,656	23,510	69,485	19,439	249,023	28,827	24,074	19,671	41,904	27,533	43,640	30,047	23,476	26,736	33,971	24,273	28,858	24,523	25,668	22,810	25,789	27,662	29,572	22,097	24,622	33,562	19,339	20,487	15,760	23,242	28,073	19,855	12,315	18,203	44,188	19,933	26,494	19,853	12,127	0	0	0
Capital Expenditures	1,731	1,565	2,202	1,942	2,677	137	355	871	1,760	890	366	868	1,067	284	1,070	806	10,925	3,977	2,166	2,944	1,737	2,690	1,062	819	1,128	1,119	1,547	732	431	912	1,730	2,878	2,571	817	676	753	46	60	92	40	50	70	203	372	157	228	857	3,082	1,022	216	111	71	189	60	66	69	83	284	775	665	1,004	604	897	162	190	67	208	204	2,032	3,041	228
Cash And Cash Equivalents Changes	0	0	57,541	10,361	-146,919	62,330	11,123	-8,256	-138,707	211,985	-7,975	23,040	-51,050	42,642	40,580	-16,183	-27,678	-51,837	122,851	18,903	-124,119	128,519	-39,235	64,455	-15,073	26,739	-7,361	-142,271	153,911	-30,541	40,146	-45,975	50,046	-229,584	220,196	4,753	4,403	-22,233	14,371	-16,107	13,593	6,571	-3,260	-7,235	9,698	-4,585	4,335	-1,145	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-4,152	7,330	4,894	3,199	2,806	2,569	-27,981	4,441	-2,221	8,937	-59	-6,169	-3,396	9,344	-19,873	5,120	-3,689	-1,623	886	-3,367	-1,757	5,851	-16,414	-178,589	3,761	-6,056	-1,507	2,967	-1,050	-471	-1,550	1,033	138	21	-1,140	-811	509	3,761	-2,953	-231	-844	779	-1,787	-972	249	5,757	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-16,326	51,939	49,350	11,868	-128,418	41,672	2,038	-11,633	-139,615	209,283	-8,261	21,887	-47,263	46,163	41,369	-20,448	-23,358	-53,487	124,260	16,553	-121,455	128,389	-41,111	65,315	-15,073	26,739	-7,361	-142,271	153,911	-30,541	40,146	-45,975	50,046	-229,584	220,196	4,753	4,403	-22,233	14,371	-16,107	13,593	6,571	-3,260	-7,235	9,698	-4,585	4,335	-1,145	2,858	-2,979	-1,873	-1,910	7,475	-2,525	-8,940	14,223	-1,148	4,727	-7,482	-4,831	8,218	7,540	-5,888	-25,985	24,255	-6,561	6,641	7,726	0	0	0
Change In Working Capital	696	-32,742	-4,855	-3,152	-51,307	-3,114	26,396	-11,855	5,967	8,024	-56	-32,520	-840	1,385	12,569	-45,178	20,413	-6,677	9,336	-11,462	1,607	15,711	-18,110	-3,935	-15,116	-1,669	-1,034	-7,968	11,202	-737	524	-9,854	1,461	12,343	782	-248	4,126	526	1,241	3,495	259	-353	3,674	1,283	3,366	7,622	-4,105	887	-4,895	-2,173	-198	-5,244	34,421	241	-1,183	-2,301	-46,029	-577	545	-857	-2,276	-1,443	-639	-1,133	52,761	2,776	-2,385	-2,164	22,547	0	0
Change Receivables	0	0	4,072	-1,367	-9,904	-3,002	-3,424	-1,000	-1,817	-3,245	-3,966	839	-374	-457	-2,030	-8,358	1,530	-5,815	-5,828	-1,001	-8,112	861	-4,996	-1,047	-3,437	-2,062	-1,714	-512	-556	-863	0	0	0	0	0	0	293	183	-114	721	1,362	-1,097	284	1,917	-41	4,053	-2,936	742	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-11,494	-11,319	4,072	-1,367	-9,904	-3,002	-3,424	-1,000	-1,817	-3,245	-3,966	839	-374	-457	-2,030	-8,358	1,530	-5,815	-5,828	-1,001	-8,112	861	-4,996	-1,047	-3,437	-2,062	-1,714	-512	-556	-2,801	0	0	-1,419	0	0	293	293	183	-114	721	1,362	-1,097	284	1,917	1,818	1,859	0	742	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Inventory	-2,381	-14,750	-24,325	-3,158	-10,256	1,376	1,725	1,812	-4,768	1,423	-5,186	741	-6,821	831	1,602	-251	-3,098	-108	-2,253	345	-2,156	1,400	-196	-3,253	2,489	-3,035	-108	-243	-146	-3,298	-207	0	-3,651	0	0	0	-1,140	-812	-67,728	-60,323	-3,827	286	-225	517	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	9,481	31,692	-72	-31,842	2,794	37,234	-14,563	29,498	6,417	11,706	-40,191	12,814	492	11,335	-35,251	38,028	-3,739	21,311	-8,858	13,431	15,485	-1,454	-10,347	-474	17,334	-3,026	-1,271	10,051	4,789	1,674	-9,383	611	13,710	644	-269	4,973	1,213	846	-987	2,724	458	3,615	-1,151	2,600	3,988	-1,300	-3,236	1,418	0	0	0	0	0	0	0	839	3,963	2,193	0	0	0	280	0	1,566	0	0	0	6,586	1,566	0
Change To Netincome	0	13,023	16,914	30,206	20,219	15,339	5,962	36,079	15,675	15,386	13,146	20,825	12,802	24,218	9,123	13,527	13,540	9,496	14,916	50,250	9,046	8,354	9,598	5,621	19,349	220,033	6,492	12,407	17,914	1,285	17,131	7,936	7,747	1,646	3,362	3,053	2,222	1,126	1,158	1,816	2,583	1,517	1,583	1,574	1,448	1,599	1,757	1,415	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-16,154	-24,231	-24,231	695	-4,282	-9,139	1,896	-25,799	3,429	-2,610	6,091	-6,459	1,769	1,662	-1,318	-12,047	2,985	-3,894	-448	-306	-2,035	-6,464	10,712	-17,128	-1,306	3,814	-6,305	-926	-2,049	-943	0	-265	0	0	0	2,193	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	2,182	2,228	2,206	1,257	1,311	1,286	1,334	1,411	1,518	1,520	1,567	1,604	2,547	2,496	2,039	1,764	1,514	1,116	1,154	991	1,201	1,073	973	969	1,107	850	813	823	906	896	767	673	577	395	353	508	364	375	396	412	401	429	450	439	421	422	442	420	342	379	426	438	481	511	530	536	547	561	519	505	457	383	332	321	313	315	312	297	0	0	0
Dividends Paid	0	-2,347	-1,202	0	1,119	10,611	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	246,994	266,272	214,333	164,983	153,115	281,533	239,861	237,823	249,456	389,071	179,788	188,049	166,162	213,425	167,262	125,893	146,343	169,701	223,188	98,928	82,375	203,830	75,441	116,552	49,060	64,133	37,394	44,755	187,026	33,115	63,656	23,510	69,485	19,439	249,023	28,827	24,074	19,671	41,904	27,533	43,640	30,047	23,476	26,736	33,971	24,273	28,858	24,523	25,668	22,810	25,789	27,662	29,572	22,097	24,622	33,562	19,339	20,487	15,760	23,242	28,073	19,855	12,315	18,203	44,188	19,933	26,494	19,853	12,127	0	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	296	416	534	80	232	317	-585	-95	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	1,727	-39,912	-18,335	-20,011	-83,449	-11,489	-16,217	-59,186	-72,274	-24,590	-36,289	-73,222	-50,889	-42,292	-34,588	-108,748	-68,757	-59,530	-60,651	-81,490	-62,414	-135,452	-58,057	-50,340	-74,895	-51,074	-43,466	-50,576	-32,416	-41,790	-34,465	-47,814	-38,082	-21,834	-23,312	-21,728	-14,554	-15,182	-11,911	-10,260	-8,170	-13,583	-10,464	-14,272	-7,531	-7,428	-11,988	-11,121	-13,543	-13,204	-10,718	-13,377	22,176	-11,123	-11,922	-13,498	-10,675	-11,758	-11,230	-11,515	-15,302	-8,229	-8,641	-7,358	42,222	-6,171	-10,588	-10,940	0	0	0
Investments	-23,957	35,765	52,203	38,197	-67,438	74,378	26,647	59,084	-66,329	35,462	26,079	87,433	-21,709	-153,777	71,082	94,052	37,888	7,170	-12,902	83,009	-62,064	117,167	11,789	-181,784	52,662	-172,792	45,095	-91,680	35,776	-28,703	-8,067	2,436	87,977	-120,192	10,331	22,418	-79,688	-29,415	8,027	-5,762	-7,916	20,254	7,303	7,137	16,768	-15,008	16,739	-53,606	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	29,827	36,555	24,199	2,354	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	-31	-23	-23	-191	-51	-21	-20	-19	-71	-21	-368	-18	230,680	-17	-21	-243	-79	-23	-75	-142	146,546	-71	-71	-68	-70	-71	-99	162,461	-71	29,953	0	34,709	50,000	-15,291	0	-299	-100	-99	-100	14,679	-100	-99	-100	-203	-413	-413	682	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-33,843	-21,577	-43,232	-52,932	-55,865	-33,286	-62,157	-85,260	-83,277	-50,294	-51,225	-65,664	-71,401	-64,011	-52,492	-88,948	-89,729	-61,809	-84,551	-120,299	-78,081	-159,163	-61,835	-49,916	-69,208	-111,665	-48,137	-54,992	-58,647	-46,654	-51,050	-43,691	-42,896	-37,801	-27,133	-24,288	-21,220	-17,149	-14,614	-15,943	-12,237	-14,589	-15,349	-17,458	-10,015	-16,290	-9,343	-13,137	-8,662	-9,759	-12,641	-13,350	-15,088	-15,357	-11,315	-13,176	32,956	-13,428	-13,623	-12,472	-14,150	-8,181	-9,293	-7,731	-11,773	-10,303	-9,396	-9,695	0	0	0
Other Cashflows From Financing Activities	-3,155	5,789	1,901	2,655	2,960	-508	9,992	859	-199,835	201,184	2,256	9,197	-20,716	393,980	4,103	-1,466	3,434	602	7,433	17,459	475	146,880	7,104	2,066	6,959	7,223	-9,453	-24	269,644	456	83,263	-502	15,268	53,676	248,468	4,063	1,875	2,072	10	15	14,778	20,184	7,100	6,765	664	126	3	1,832	-45,214	11	318	30	3	-3	-2	11	12	940	2,852	14	-380	-380	-385	-383	-372	-364	208	-314	0	0	0
Other Cashflows From Investing Activities	0	0	0	0	3,411	0	0	0	0	0	0	0	0	0	0	94,052	115,165	77,277	70,107	83,009	-114,892	0	0	0	0	0	0	0	482	0	0	0	0	-141,060	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	44,568	-5,895	-6,908	6,803	6,454	8,534	6,102	6,738	-8,663	5,027	1,666	1,026	7,788	2,941	1,016	1,162	-1,523	2,723	5,436	39,155	3,708	3,895	2,972	3,701	6,136	221,712	853	6,214	13,173	1,531	39,692	3,653	2,304	1,308	179	1,093	612	-524	-330	556	1,954	-517	-619	262	-2,594	-16,843	-9,225	-10,761	35,008	-13,135	-28,069	3,432	946	2,059	-1,391	-204	186	1	7	2	1,627	1,616	1,856	1,347	1,111	1,108	1,089	826	0	0	0
Sale Purchase Of Stock	0	-2,347	-1,202	-12,806	-2,212	9,278	-9,278	-8,993	-197,879	201,446	2,500	23,391	22,254	9,294	4,657	6,077	3,668	1,048	191,801	4,765	652	912	7,219	298,562	7,461	250,323	1,289	33,115	33,115	40,059	58,310	155	513	3,567	250,085	4,063	98,645	22,464	18,344	15	15,000	0	0	0	664	18,264	-3	62,900	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	18,095	16,511	16,577	34,894	18,626	14,772	12,463	30,651	13,907	11,841	11,736	20,354	12,239	15,908	8,408	12,596	12,908	8,843	9,935	12,744	8,387	7,054	6,341	7,478	6,034	5,500	5,537	6,030	4,417	4,339	4,465	4,283	3,043	2,738	2,231	1,960	1,610	1,650	1,488	1,260	1,503	1,517	1,583	1,574	1,448	1,598	1,757	1,388	1,436	1,941	3,884	1,418	1,484	1,483	1,503	1,716	1,748	1,970	2,097	1,972	6,446	0	0	705	2,816	0	0	0	0	0	0
Total Cash From Financing Activities	8,210	37,619	23,673	-7,825	557	-559	693	-8,154	-104	201,113	2,235	8,829	21,548	238,711	4,086	-1,487	3,191	523	196,404	17,384	359	146,804	7,033	296,579	6,864	250,189	-9,524	-95	150,319	39,635	83,263	-502	151	53,502	233,177	4,063	98,645	22,364	18,255	-85	29,679	-100	-99	-100	461	17,851	-416	63,582	-313	-303	5	-323	27,727	-372	-446	16,749	-327	657	2,701	-262	-294	-217	-354	-133	-291	-252	68,509	23,945	66,170	41,254	13,906
Total Cash From Operating Activities	3,458	-38,347	-16,133	-18,069	-80,772	-11,626	-15,862	-58,315	-70,514	-23,700	-35,923	-72,354	-49,822	-42,008	-33,518	-107,942	-57,832	-55,553	-58,485	-78,546	-60,677	-132,762	-56,995	-49,521	-73,767	-49,955	-41,919	-49,844	-31,985	-40,878	-32,735	-44,936	-35,511	-21,017	-22,636	-20,975	-14,508	-15,122	-11,819	-10,220	-8,120	-13,513	-10,261	-13,900	-7,374	-7,200	-11,131	-8,039	-12,521	-12,988	-10,607	-13,306	22,365	-11,063	-11,856	-13,429	-10,592	-11,474	-10,455	-10,850	-14,298	-7,625	-7,744	-7,196	42,412	-6,104	-10,380	-10,736	0	0	0
Total Cashflows From Investing Activities	0	35,765	50,001	36,255	-66,704	74,515	26,292	58,213	-68,089	34,572	25,713	86,565	-22,776	-154,061	70,012	93,246	26,963	3,193	-15,068	80,065	-63,801	114,477	10,727	-182,603	51,534	-173,911	43,548	-92,412	35,345	-29,615	-9,797	-442	85,406	-262,069	9,655	21,665	-79,734	-27,342	7,935	-5,802	-7,966	20,184	7,100	6,765	16,611	-15,236	15,882	-56,688	46,452	30,760	20,448	11,719	0	23,175	14,265	10,903	31,868	22,097	6,553	6,281	21,746	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31
Cost Of Revenue	45,199	38,599	34,466	31,044	21,963	14,404	6,236	833	41,060	22,390	13,593	20,386	24,249	13,338	20,663	10,042	12,452	17,693	8,062	4,573	-
Depreciation And Amortization	7,873	12,542	3,817	11,291	-28,226	4,216	3,593	3,242	1,833	1,547	1,719	1,705	1,585	2,058	2,132	1,493	1,237	952	667	0	132
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	-73,494	-204,426	-199,920	-243,854	-300,740	-320,648	-200,776	-178,252	-125,196	-68,518	-62,019	-52,594	-50,727	-55,682	-4,831	-43,956	-45,656	-45,656	-20,551	-8,807	-6,600
Ebitda	-65,621	-191,884	-196,103	-232,563	-328,966	-316,432	-197,183	-175,010	-123,363	-66,971	-60,300	-50,889	-49,142	-53,624	-2,699	-42,463	-44,419	-44,703	-19,883	-8,807	-6,468
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	0	0	0	0	0	100	2,700	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	354,157	290,634	271,048	229,842	160,274	76,841	30,694	4,125	0	1,224	363	18,411	21,434	922	64,358	14,967	1,784	0	0	0	-
Income Before Tax	-150,101	-242,039	-241,554	-274,254	-355,910	-349,089	-449,121	-203,781	-132,118	-70,039	-63,145	-52,030	-48,041	-56,075	-6,567	-39,355	-41,167	-46,345	-20,584	0	-6,768
Income Tax Expense	1,483	-5,471	8,906	2,598	478	-94	-165,119	-3,739	1,498	-1,113	-3,512	-3,245	-3,629	-1,139	278	0	351	-514	-612	8,807	-
Interest Expense	50,149	37,119	32,471	22,425	18,872	22,402	17,240	5,398	1,578	1,484	46	89	148	260	278	0	348	0	0	0	0
Interest Income	7,379	3,024	509	3,226	10,249	10,461	4,096	1,602	649	0	0	0	0	0	0	0	0	0	0	0	-
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	-151,584	-236,568	-250,460	-276,852	-356,388	-348,995	-284,002	-200,042	-132,118	-68,926	-59,633	-48,785	-44,412	-54,936	-6,567	-39,355	-41,167	-46,345	-19,972	-8,807	-6,768
Net Income Applicable To Common Shares	0	-236,568	-250,460	-276,852	-356,388	-348,995	-284,002	-200,042	-132,118	-68,926	-59,633	-48,785	-44,412	0	0	0	0	0	0	0	-
Net Income From Continuing Ops	-173,606	-236,568	-250,460	-276,852	-356,388	-348,995	-284,002	-200,042	-132,118	-68,926	-59,633	-48,785	-44,412	0	0	0	0	0	0	0	-
Net Interest Income	-41,038	-34,095	-31,962	-19,199	-8,623	-11,941	-13,144	-3,796	0	0	0	0	0	0	0	0	0	0	0	0	-
Non Operating Income Net Other	0	7,200	-2,649	-4,831	-33,001	2,129	10,104	-16,493	-103	146	1,082	990	2,994	0	0	0	0	0	0	0	-
Non Recurring	0	6,616	0	0	0	0	465,427	69	15	-63	1,988	0	0	0	0	0	0	0	0	0	-
Operating Income	-73,494	-204,426	-199,920	-243,854	-300,740	-328,777	-441,985	-181,890	-130,437	-68,701	-64,181	-52,931	-50,887	-55,838	-7,350	-43,956	-45,805	-46,859	-20,831	-8,807	-6,600
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	472,850	533,659	505,434	504,740	482,977	416,722	247,810	180,019	126,045	69,888	62,556	71,342	72,321	56,760	70,186	58,923	47,589	46,859	20,831	8,807	6,600
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Reconciled Depreciation	7,002	5,342	6,209	8,846	4,775	4,216	3,593	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Research Development	152,381	276,677	272,049	308,443	286,378	270,902	149,310	104,793	76,943	47,624	41,944	50,273	50,856	39,042	48,081	37,764	31,074	33,630	13,652	1,728	4,433
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Selling General Administrative	259,305	214,119	199,224	156,407	169,861	127,200	88,671	71,151	47,269	20,717	18,893	19,364	19,880	15,660	19,973	19,666	15,278	28,214	12,467	3,809	-
Tax Provision	-14,914	-5,471	8,906	2,598	478	-94	-165,119	-3,739	0	0	0	0	0	0	0	0	0	0	0	0	-
Total Operating Expenses	427,651	495,060	470,968	473,696	461,014	402,318	241,574	179,186	126,045	69,888	62,556	71,342	72,321	56,760	70,186	58,923	47,589	46,859	20,831	-8,807	6,600
Total Other Income Expense Net	-76,607	-37,613	-41,634	-30,400	-55,170	-11,671	-225,097	-24,924	-5,424	-114	-1,080	674	2,834	-133	-1,458	4,601	-149	-1,203	-280	0	-168
Total Revenue	399,356	329,233	305,514	260,886	182,237	91,245	36,930	4,958	0	1,224	363	18,411	21,434	922	64,358	14,967	1,784	0	0	0	-

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31
Cost Of Revenue	13,506	9,946	9,114	6,942	9,384	13,436	8,197	7,582	7,851	11,696	8,380	6,539	9,417	8,399	6,676	6,552	6,945	5,596	5,367	4,055	4,344	4,310	3,135	2,615	2,610	1,790	1,061	775	489	344	5,527	11,506	12,228	11,785	8,740	8,307	8,167	5,915	4,181	4,112	2,857	3,664	2,938	4,134	3,866	3,680	6,022	6,818	8,144	6,915	4,752	4,438	3,942	3,225	2,830	3,341	3,996	5,498	6,533	4,636	3,606	2,217	2,545	1,674	2,266	3,577	3,053	3,556	8,233	2,954	3,231	3,275	8,062	-	-	-	4,573
Depreciation And Amortization	2,182	2,228	2,206	-2,482	-15,345	15,483	8,958	3,446	1,518	1,520	1,567	1,604	2,547	2,496	2,039	1,764	1,514	1,116	1,154	991	1,201	1,073	973	969	1,107	850	813	823	906	896	767	673	577	395	353	508	363	375	396	412	401	429	450	439	421	422	442	420	342	380	426	438	481	511	530	536	547	561	519	505	457	383	332	321	313	315	312	297	0	-	-	-	0	-	-	-	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Ebit	-3,692	-31,435	-26,554	-37,385	-40,744	-33,273	-60,498	-69,911	-70,398	-38,766	-37,529	-55,619	-64,853	-48,190	-44,439	-83,927	-85,473	-57,245	-78,729	-112,294	-67,832	-153,199	-49,034	-50,581	-61,029	-50,820	-42,858	-46,068	-48,965	-49,489	-40,254	-39,544	-40,097	-36,476	-25,717	-22,906	-21,443	-17,357	-14,626	-15,091	-13,775	-15,099	-15,959	-17,186	-15,842	-16,824	-9,231	-10,718	-13,006	-13,103	-14,678	-9,940	-16,501	-13,232	-12,651	-13,297	34,537	-13,345	-13,582	-12,443	-14,877	-9,300	-10,491	-9,288	-13,483	-11,806	-10,198	-10,168	0	0	0	0	0	-	-	-	0
Ebitda	-1,510	-29,207	-24,348	-39,867	-56,089	-17,790	-51,540	-66,465	-68,880	-37,246	-35,962	-54,015	-62,306	-45,694	-42,400	-82,163	-83,959	-56,129	-77,575	-111,303	-66,631	-152,126	-48,061	-49,612	-59,922	-49,970	-42,045	-45,245	-48,059	-48,593	-39,487	-38,871	-39,520	-36,081	-25,364	-22,398	-21,080	-16,982	-14,230	-14,679	-13,374	-14,670	-15,509	-16,747	-15,421	-16,402	-8,789	-10,298	-12,664	-12,723	-14,252	-9,502	-16,020	-12,721	-12,121	-12,761	35,084	-12,784	-13,063	-11,938	-14,420	-8,917	-10,159	-8,967	-13,170	-11,491	-9,886	-9,871	-11,586	-11,586	-11,586	-11,586	-4,993	-4,993	-4,993	-4,993	0
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Gross Profit	101,576	93,555	85,389	79,328	78,712	68,255	72,534	71,133	74,303	67,849	69,033	59,863	61,154	59,038	55,677	53,973	48,348	43,172	38,763	29,991	28,300	16,286	18,174	14,081	12,119	9,084	6,097	3,394	2,342	1,783	0	0	0	0	0	0	-1,224	293	475	456	324	39	0	0	0	5,798	10,637	7,774	5,630	5,798	4,040	5,966	922	0	0	49,476	49,476	4,913	5,361	4,606	4,345	3,653	3,807	3,160	1,784	0	0	0	0	0	0	0	0	-	-	-	0
Income Before Tax	-31,660	-24,705	-40,517	-53,219	-70,079	-29,263	-61,246	-81,451	-80,296	-50,476	-46,700	-64,082	-73,594	-63,284	-48,789	-88,587	-89,885	-62,060	-83,834	-120,131	-77,071	-159,214	-61,494	-51,308	-69,749	-276,349	-48,087	-54,936	-61,680	-46,907	-51,503	-43,691	-42,896	-37,800	-27,133	-24,288	-22,332	-17,149	-14,614	-15,943	-15,749	-14,589	-15,349	-17,458	-13,260	-16,290	-9,343	-13,137	-12,291	-9,759	-12,641	-13,350	-16,227	-15,357	-11,315	-13,176	32,956	-13,429	-13,623	-12,472	-14,150	-8,330	-9,219	-7,656	-11,773	-10,303	-9,396	-9,695	0	0	0	0	0	-	-	-	0
Income Tax Expense	2,183	3,128	2,715	-287	-14,214	4,023	911	3,809	2,981	-182	4,525	1,582	-2,193	727	3,703	361	-156	-251	717	168	1,010	-51	339	-1,392	-541	-164,683	49	56	-3,033	-253	-453	893	864	-37	328	343	-1,113	366	364	346	-3,512	7	9	10	-3,245	19	15	43	-3,629	32	41	48	-1,139	66	55	83	1,595	129	269	526	0	-150	75	75	351	0	-888	-537	11,586	11,586	11,586	11,586	4,993	4,993	4,993	4,993	0
Interest Expense	12,827	-12,986	12,492	11,844	11,095	9,620	8,257	8,147	8,164	8,165	8,150	7,992	8,277	6,784	3,635	3,729	3,767	4,026	4,625	6,454	8,639	4,715	4,560	4,488	4,420	4,351	4,179	4,290	1,881	1,517	1,055	945	851	17	338	372	378	377	374	355	20	7	9	10	12	19	15	43	27	32	41	48	57	66	55	83	123	84	41	29	49	49	59	70	434	90	86	92	73	75	73	52	82	-	-	-	550
Interest Income	1,671	1,471	1,737	2,199	1,972	563	356	133	186	108	50	165	328	518	865	1,515	2,259	2,752	2,599	3,815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Income	-33,843	-21,577	-43,232	-52,932	-55,865	-33,286	-62,157	-85,260	-83,277	-50,294	-51,225	-65,664	-71,401	-64,011	-52,492	-88,948	-89,729	-61,809	-84,551	-120,299	-78,081	-159,163	-61,833	-49,916	-69,208	-111,666	-48,136	-54,992	-58,647	-46,654	-51,050	-43,691	-42,896	-37,800	-27,133	-24,288	-21,219	-17,149	-14,614	-15,943	-12,237	-14,589	-15,349	-17,458	-10,015	-16,290	-9,343	-13,137	-8,662	-9,759	-12,641	-13,350	-15,088	-15,357	-11,315	-13,176	32,956	-13,429	-13,623	-12,472	-14,150	-8,180	-9,294	-7,731	-11,773	-10,303	-9,396	-9,695	-11,586	-11,586	-11,586	-11,586	-4,993	-4,993	-4,993	-4,993	0
Net Income Applicable To Common Shares	0	-21,577	-43,232	-52,932	-55,865	-33,286	-62,157	-85,260	-83,277	-50,294	-51,225	-65,664	-71,401	-64,011	-52,492	-88,948	-89,729	-61,809	-84,551	-120,299	-78,083	-159,163	-61,833	-49,916	-69,208	-111,666	-48,136	-54,992	-58,647	-46,654	-51,050	-43,691	-42,897	-37,800	-27,133	-24,288	-21,220	-17,149	-14,614	-15,943	-12,237	-14,589	-15,349	-17,458	-10,015	-16,290	-9,343	-13,137	0	-9,759	-12,641	0	0	0	0	0	32,956	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Income From Continuing Ops	-33,843	-21,577	-43,232	-52,932	-55,865	-33,286	-62,157	-85,260	-83,277	-50,294	-51,225	-65,664	-71,401	-64,011	-52,492	-88,948	-89,729	-61,809	-84,551	-120,299	-78,083	-159,163	-61,833	-49,916	-69,208	-111,666	-48,136	-54,992	-58,647	-46,654	-51,050	-43,691	-42,897	-37,800	-27,133	-24,288	-21,220	-17,149	-14,614	-15,943	-12,237	-14,589	-15,349	-17,458	-10,015	-16,290	-9,343	-13,137	0	-9,759	-12,641	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Net Interest Income	-11,156	-11,515	-10,755	-9,645	-9,123	-9,057	-7,901	-8,014	-7,978	-8,057	-8,100	-7,827	-7,949	-6,266	-2,770	-2,214	-1,508	-1,274	-2,026	-3,815	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Non Operating Income Net Other	0	0	-9,165	-3,739	-16,656	14,197	7,624	2,035	14	88	284	-3,035	-482	-3,739	6,191	-6,801	2,905	-729	-2,779	-32,398	1,088	1,682	-10,003	9,362	2,348	3,234	3,153	1,369	-14,392	-450	-1,906	255	-655	262	148	142	43	44	26	33	61	553	665	-197	2,675	645	19	-2,349	0	3,407	2,124	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Non Recurring	0	0	1,134	0	0	0	0	6,616	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2,327,135	465,427	-2,327,135	465,427	98	11	8	50	-28	7	26	10	11	15	-81	-8	1,988	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Operating Income	-3,692	-17,023	-18,860	-37,385	-40,744	-33,273	-60,498	-69,911	-72,146	-42,399	-38,834	-53,055	-64,835	-52,761	-51,345	-78,057	-89,023	-57,305	-76,430	-81,279	-69,483	-156,181	-46,931	-56,182	-67,677	-275,232	-47,061	-52,015	-45,407	-44,940	-48,542	-43,001	-41,390	-38,045	-26,943	-24,058	-21,997	-16,816	-14,266	-15,621	-15,790	-15,135	-16,005	-17,251	-15,923	-16,916	-9,347	-10,745	-13,030	-13,134	-14,724	-9,999	-16,536	-13,265	-12,686	-13,350	32,942	-13,474	-13,851	-12,969	-14,877	-9,300	-10,491	-9,288	-13,483	-11,806	-10,284	-10,232	-11,586	-11,586	-11,586	-11,586	-4,993	-4,993	-4,993	-4,993	0
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0
Other Operating Expenses	118,774	116,301	111,892	123,655	128,840	114,964	141,229	148,626	152,566	118,656	115,226	118,986	134,942	119,164	112,983	137,651	143,671	105,284	120,080	113,942	101,527	175,477	67,940	71,778	78,106	64,929	53,169	51,606	50,706	51,166	38,348	39,799	40,394	36,738	25,865	23,048	21,486	17,694	15,127	15,580	14,126	15,174	16,005	17,251	15,923	16,916	19,984	18,519	18,660	18,932	18,764	15,965	17,458	13,265	12,686	13,350	15,012	18,387	19,212	17,575	19,222	12,953	14,298	12,448	15,267	11,806	10,284	10,232	11,586	11,586	11,586	11,586	4,993	4,993	4,993	4,993	0
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Reconciled Depreciation	2,182	2,228	2,206	1,257	1,311	1,286	1,334	1,411	1,518	1,520	1,567	1,604	2,547	2,496	2,039	1,764	1,514	1,116	1,154	991	1,201	1,073	973	969	1,107	850	813	823	906	896	767	673	577	395	353	508	364	375	396	412	401	429	450	439	421	422	442	420	342	379	426	438	481	511	530	536	547	561	519	505	457	383	332	321	313	315	312	297	0	-	-	-	0	-	-	-	0
Research Development	35,029	40,704	35,149	41,499	63,871	52,970	78,319	81,517	85,596	59,333	63,003	64,117	79,293	70,419	69,611	89,120	91,912	58,892	70,981	64,593	57,217	138,227	34,660	40,798	45,808	40,641	31,985	30,876	30,630	32,457	18,281	23,425	22,625	20,971	17,234	16,113	15,605	12,049	9,978	9,992	9,120	10,110	10,725	11,989	11,047	11,499	13,723	14,004	14,401	13,711	11,618	11,125	13,154	8,862	8,137	8,889	10,127	12,609	13,470	11,875	13,775	8,200	8,848	6,941	9,670	7,537	6,783	7,085	5,953	3,771	3,460	2,753	5,590	-	-	-	1,728
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Selling General Administrative	70,239	65,651	65,760	74,208	55,858	47,839	53,494	58,116	59,335	49,395	42,276	43,685	43,685	37,850	34,657	40,215	43,300	39,680	42,578	44,303	38,765	31,867	29,172	27,396	28,581	21,647	19,311	19,132	18,681	17,469	19,300	15,701	17,192	15,372	8,278	6,427	5,518	5,270	4,753	5,176	4,605	4,635	4,830	4,823	4,455	4,995	5,819	4,095	3,917	4,841	6,720	4,402	3,823	3,892	4,020	3,925	4,338	5,217	5,223	5,195	4,990	4,371	5,118	5,186	5,284	3,954	3,189	6,379	9,985	7,553	6,023	4,653	12,467	-	-	-	3,809
Tax Provision	2,183	-3,128	2,715	-287	-14,214	4,023	911	3,809	2,981	-182	4,525	1,582	-2,193	727	3,703	361	-156	-251	717	168	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0
Total Operating Expenses	105,268	106,355	102,778	116,713	119,456	101,528	133,032	141,044	144,715	106,960	106,846	112,447	125,525	110,765	106,307	131,099	136,726	99,688	114,713	109,887	97,183	171,167	64,805	69,163	75,496	63,139	52,108	50,831	50,217	50,822	38,348	39,799	40,394	36,738	25,865	23,048	21,486	17,694	15,127	15,580	14,126	15,174	16,005	17,251	15,923	16,916	19,984	18,519	18,660	18,932	18,764	15,965	17,458	13,265	12,686	13,350	15,012	18,387	19,212	17,575	19,222	12,953	14,298	12,448	15,267	11,806	10,284	10,232	-11,586	-11,586	-11,586	-11,586	-4,993	-4,993	-4,993	-4,993	0
Total Other Income Expense Net	-27,968	-7,682	-12,373	-15,834	-29,335	4,010	-748	-11,540	-1,906	-3,308	-787	-3,671	-1,274	-5,291	4,611	-9,247	1	-4,270	-5,858	-36,420	-2,639	-2,339	-13,216	6,525	-3,346	-219,133	1,350	-3,968	-12,428	3,189	-12,431	-3,254	-1,935	-1,361	-1,088	-1,039	-558	574	376	-506	-1,954	517	619	-262	2,594	553	-97	-2,376	742	3,376	2,078	-3,362	331	-2,059	1,391	204	14	45	228	497	727	970	1,272	1,632	1,710	1,503	-86	-64	0	0	0	0	0	-	-	-	0
Total Revenue	115,082	103,501	94,503	86,270	88,096	81,691	80,731	78,715	82,154	79,545	77,413	66,402	70,571	67,437	62,353	60,525	55,293	48,768	44,130	34,046	32,644	20,596	21,309	16,696	14,729	10,874	7,158	4,169	2,831	2,127	0	0	0	0	0	0	-1,224	293	475	456	324	39	0	0	18,411	5,798	10,637	7,774	5,630	5,798	4,040	5,966	922	0	0	49,476	49,476	4,913	5,361	4,606	4,345	3,653	3,807	3,160	1,784	0	0	0	0	0	0	0	0	-	-	-	0

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	399,356
Cost of Revenue	-45,199
Gross Profit	354,157	354,157

Operating Income (+$)
Gross Profit	354,157
Operating Expense	-427,651
Operating Income	-73,494	-73,494

Operating Expense (+$)
Research Development	152,381
Selling General Administrative	259,305
Selling And Marketing Expenses	0
Operating Expense	427,651	411,686

Net Interest Income (+$)
Interest Income	7,379
Interest Expense	-50,149
Other Finance Cost	-1,732
Net Interest Income	-41,038

Pretax Income (+$)
Operating Income	-73,494
Net Interest Income	-41,038
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-150,101	3,113 EBIT - interestExpense = -123,643 -150,101 -101,435
Interest Expense	50,149
Earnings Before Interest and Taxes (EBIT)	-73,494	-99,952
Earnings Before Interest and Taxes (EBITDA)	-65,621

After tax Income (+$)
Income Before Tax	-150,101
Tax Provision	--14,914
Net Income From Continuing Ops	-173,606	-135,187
Net Income	-151,584
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	472,850
Total Other Income/Expenses Net	-76,607	41,038

Technical Analysis of Amicus Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amicus Therapeutics Inc. The general trend of Amicus Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amicus Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (-71.4%)		Bearish trend (71.4%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Amicus Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11.11 < 11.82 < 11.97.

The bearish price targets are: 9.7 > 9.1 > 8.9375.

Tweet this

Amicus Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amicus Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending down: The MA 200 is trending down. -1
Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Amicus Therapeutics Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amicus Therapeutics Inc. The current macd is -0.41840596.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Amicus Therapeutics Inc price going down in the near term. -2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Amicus Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Amicus Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Amicus Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Amicus Therapeutics Inc. The current adx is 31.42.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Amicus Therapeutics Inc shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.

Amicus Therapeutics Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amicus Therapeutics Inc. The current sar is 11.04.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Amicus Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amicus Therapeutics Inc. The current rsi is 39.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Amicus Therapeutics Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amicus Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amicus Therapeutics Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Amicus Therapeutics Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amicus Therapeutics Inc. The current cci is -66.13775696.

Amicus Therapeutics Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amicus Therapeutics Inc. The current cmo is -15.72754069.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Amicus Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Amicus Therapeutics Inc. The current willr is -63.29113924.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Amicus Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Amicus Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Amicus Therapeutics Inc.

Amicus Therapeutics Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amicus Therapeutics Inc. The current atr is 0.3770107.

Amicus Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amicus Therapeutics Inc. The current obv is 90,332,619.

Amicus Therapeutics Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amicus Therapeutics Inc. The current mfi is 45.25.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Amicus Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Amicus Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-29	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-11-30	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-12	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-13	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-18	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-19	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-20	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-26	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-03	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-12	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-16	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-01-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-19	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-01-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-01-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-29	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-30	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-31	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-02	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-02-06	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-07	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-02-08	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-02-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-13	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-15	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-27	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-28	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-04	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-06	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-19	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-20	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-03-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-25	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-28	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-03	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-12	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-18	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-19	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.

6.3. Candlestick Patterns

Amicus Therapeutics Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Amicus Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	39.815
Ma 20	Greater than	Ma 50	11.217
Ma 50	Greater than	Ma 100	12.153
Ma 100	Greater than	Ma 200	12.408
Open	Greater than	Close	10.700
Total			1/5 (20.0%)

Create your own Symbol Scanner

Get notifications about Amicus Therapeutics Inc

I send you an email if I find something interesting about Amicus Therapeutics Inc.

Amicus Therapeutics Inc Buy, Hold or Sell?

Let's analyse Amicus Therapeutics Inc together

Get notifications about Amicus Therapeutics Inc

Quick analysis of Amicus Therapeutics Inc (30 sec.)

What can you expect buying and holding a share of Amicus Therapeutics Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Amicus Therapeutics Inc (5 min.)

$10.82

$0.54

$-4.12 - $5.58

$-3.57 - $6.13

2. Growth of Amicus Therapeutics Inc (5 min.)

Is Amicus Therapeutics Inc growing?

How much money is Amicus Therapeutics Inc making?

How much money comes from the company's main activities?

3. Financial Health of Amicus Therapeutics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Amicus Therapeutics Inc? (5 min.)

What can you expect buying and holding a share of Amicus Therapeutics Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Amicus Therapeutics Inc

About Amicus Therapeutics Inc

Financial Health

Valuation

1.1. Profitability of Amicus Therapeutics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Amicus Therapeutics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Amicus Therapeutics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Amicus Therapeutics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Amicus Therapeutics Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Amicus Therapeutics Inc
Buy, Hold or Sell?